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A B S T R A C T
Background
Depression is common in people with non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, cancer, and chronic
respiratory conditions. The co-existence of depression and NCDs may affect health behaviours, compliance with treatment, physiological
factors, and quality of life. This in turn is associated with worse outcomes for both conditions. Behavioural activation is not currently
indicated for the treatment of depression in this population in the UK, but is increasingly being used to treat depression in adults.
Objectives
To examine the effects of behavioural activation compared with any control group for the treatment of depression in adults with NCDs.
To examine the effects of behavioural activation compared with each control group separately (no treatment, waiting list, other
psychological therapy, pharmacological treatment, or any other type of treatment as usual) for the treatment of depression in adults with
NCDs.
Search methods
We searched CCMD-CTR, CENTRAL, Ovid MEDLINE, Embase, four other databases, and two trial registers on 4 October 2019 to identify
randomised controlled trials (RCTs) of behavioural activation for depression in participants with NCDs, together with grey literature and
reference checking. We applied no restrictions on date, language, or publication status to the searches.
Selection criteria
We included RCTs of behavioural activation for the treatment of depression in adults with one of four NCDs: cardiovascular disease,
diabetes, cancer, and chronic respiratory conditions. Only participants with a formal diagnosis of both depression and an NCD were eligible.
Studies were included if behavioural activation was the main component of the intervention. We included studies with any comparator
that was not behavioural activation, and regardless of reported outcomes.
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Data collection and analysis
We used standard methodological procedures expected by Cochrane, including independent screening of titles/abstracts and full-text
manuscripts, data extraction, and risk of bias assessments in duplicate. Where necessary, we contacted study authors for more information.
Main results
We included two studies, contributing data from 181 participants to the analyses.
Both studies recruited participants from US hospital clinics; one included people who were recovering from a stroke and the other
women with breast cancer. For both studies, the intervention consisted of eight weeks of face-to-face behavioural therapy, with one study
comparing to poststroke treatment as usual and the other comparing to problem-solving therapy.
Both studies were at risk of performance bias and potential conflict of interest arising from author involvement in the development of the
intervention. For one study, risks of selection bias and reporting bias were unclear and the study was judged at high risk of attrition bias.
Treatment efficacy (remission) was greater for behavioural activation than for comparators in the short term (risk ratio (RR) 1.53, 95%
confidence interval (CI) 0.98 to 2.38; low-certainty evidence) and medium term (RR 1.76, 95% CI 1.01 to 3.08; moderate-certainty evidence),
but these estimates lacked precision and effects were reduced in the long term (RR 1.42, 95% CI 0.91 to 2.23; moderate-certainty evidence).
We found no evidence of a difference in treatment acceptability in the short term (RR 1.81, 95% CI 0.68 to 4.82) and medium term (RR 0.88,
95% CI 0.25 to 3.10) (low-certainty evidence).
There was no evidence of a difference in depression symptoms between behavioural activation and comparators (short term: MD –1.15,
95% CI –2.71 to 0.41; low-certainty evidence). One study found no difference for quality of life (short term: MD 0.40, 95% CI –0.16 to 0.96;
low-certainty evidence), functioning (short term: MD 2.70, 95% CI –6.99 to 12.39; low-certainty evidence), and anxiety symptoms (short
term: MD –1.70, 95% CI –4.50 to 1.10; low-certainty evidence).
Neither study reported data on adverse effects.
Authors' conclusions
Evidence from this review was not sufficient to draw conclusions on the efficacy and acceptability of behavioural activation for the
treatment of depression in adults with NCDs. A future review may wish to include, or focus on, studies of people with subthreshold
depression or depression symptoms without a formal diagnosis, as this may inform whether behavioural activation could be used to treat
mild or undiagnosed (or both) depressive symptoms in people with NCDs. Evidence from low-resource settings including low- and middle-
income countries, for which behavioural activation may offer a feasible alternative to other treatments for depression, would be of interest.
P L A I N   L A N G U A G E   S U M M A R Y
Behavioural activation therapy for depression in adults with long-term physical conditions
Depression is common in adults with long-term physical conditions. Long-term physical illnesses, such as cardiovascular disease, diabetes,
cancer, or chronic respiratory conditions, can impact on mental health. Mental health problems can also affect how people cope with a
physical condition. Behavioural activation is a type of talking therapy used to treat depression in adults and it could be an alternative to
other psychological therapies or medication. This review assesses the effects of behavioural activation on depression for people with long-
term physical conditions.
We included randomised controlled trials (RCTs) of behavioural activation with adults who were diagnosed with depression and
cardiovascular disease, diabetes, cancer, or a chronic respiratory condition. An RCT is a study with a control group, in which participants
are allocated to the treatment and control groups at random. We searched a variety of online databases, including regional databases and
trial registries. The search, conducted on 4 October 2019, identified 6066 records. ANer screening records, we included two studies in this
review and 181 participants contributed data to the analyses.
Both studies recruited participants from US hospitals. One study included participants recovering from a stroke and the other included
women with breast cancer. In both studies, participants received behavioural activation delivered in eight weekly, face-to-face sessions.
One study compared behavioural activation with poststroke treatment as usual, while the other compared behavioural activation with
problem-solving therapy, a talking therapy.
Low to moderate-certainty evidence suggested that behavioural activation may be more effective in the treatment of depression than
included comparators, but these estimates were imprecise and effects were reduced in the longer term. There was no evidence of any
differences between groups in the number of people who dropped out of the studies, depression symptoms, quality of life, physical
functioning, or anxiety symptoms. The studies did not report on side effects during the study period.
There were several limitations to the included studies. In both studies, participants were aware of the treatment they received. Also,
researchers were involved in the design of the intervention in both studies, and may, therefore, have had an interest in a favourable
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outcome for behavioural activation. In one study, missing data caused by participants dropping out of the study may have influenced
results.
We did not find enough evidence in this review to know whether behavioural activation should be used to treat depression in adults with
long-term physical conditions.
Behavioural activation therapy for depression in adults with non-communicable diseases (Review)
























































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Behavioural activation compared with any comparator for depression in adults with non-communicable diseases
Behavioural activation compared with any comparator for depression in adults with non-communicable diseases
Patient or population: depression in adults with non-communicable diseases
Setting: recruitment in US hospitals
Intervention: behavioural activation
Comparison: any comparator
Anticipated absolute effects* (95% CI)Outcomes Relative ef-
fect
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— See comment — MD 1.15 lower (2.71
lower to 0.41 higher)







— See comment — MD 1.51 lower (4.14
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Quality of life (short term:
6 months)
— The mean quality of life
without behavioural ac-
tivation was 2.2
— MD 0.4 higher
(0.16 lower to 0.96
higher)
80 (1 RCT) ⊕⊕⊝⊝
Low c,f
Measured with
Quality of Life In-
ventory.
Quality of life (medium
term: 12 months)
— The mean quality of life
without behavioural ac-
tivation was 2.2
— MD 0.1 lower
(0.74 lower to 0.54
higher)
80 (1 RCT) ⊕⊕⊝⊝
Low c,f
Measured with
Quality of Life In-
ventory.
Social adjustment and
functioning (short term: 6
months)
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; HRSD: Hamilton Rating Scale for Depression; MD: mean difference; NNTB: number needed to treat for an additional beneficial outcome; RCT: ran-
domised controlled trial; RR: risk ratio; SF-36: 36-item Short Form.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aHigh risk of attrition bias in one study, potential conflict of interest in both studies, unclear allocation concealment and reporting bias in one study. Downgraded one level.
bWide confidence interval for one of the studies. For this binary outcome, there is insufficient information to give a precise estimate. Downgraded one level for imprecision.
cOne study. Did not fulfil optimal information size criterion; downgraded one level for imprecision. It is impossible to assess consistency between study results with only one
study, which means it was not possible to downgrade for inconsistency.
dDropout rates may be affected by non-random attrition because participants were not blinded to the intervention, potential conflict of interest, and unclear allocation
concealment. Downgraded one level for high risk of bias.
eConfidence interval was imprecise and covered both benefit and harm. Downgraded one level for imprecision.
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B A C K G R O U N D
Description of the condition
Depression
The term 'depression' is oNen used to describe major depressive
disorder when diagnosed in a clinical setting. It is characterised by
a period of at least two weeks of depressed mood, or a persistent
loss of interest or pleasure in activities that were previously
considered enjoyable, or both (APA 2013). A range of symptoms may
accompany these key features of depression and reduce quality
of life. These include weight loss or weight gain, insomnia or
hypersomnia, psychomotor agitation or retardation, fatigue, loss of
energy, feelings of excessive guilt and worthlessness, diminished
concentration, and recurrent thoughts of death (APA 2013).
Depression is the fiNh global cause of disease burden in terms
of years lived with a disability (YLD), and was ranked in the top
10 of YLD in 191/195 countries worldwide (Vos 2017). In 2014,
7.1% of the population living in the 28 countries of the EU was
estimated to report depression, with higher rates reported by
women, older people, and people living in cities (Eurostat 2014). In
one national survey conducted in the US, the 12-month prevalence
of depression was 10.4% and the lifetime prevalence was 20.6%
(Hasin 2018). Similarly, the lifetime prevalence for depression in
England was 19% in 2014 (HSE 2014). Global estimates of the
burden of disease show that 4.4% of people worldwide experience
depressive disorder. These figures vary considerably depending on
geographical regions; for depression, rates vary from 3.6% in the
Western Pacific to 5.4% on the African continent. More than 80% of
people who have mental disorders live in low- and middle-income
countries (Rathod 2017).
Depressive disorders can have a long-lasting impact on patients,
their families, and wider society. They oNen occur with anxiety
disorders (WHO 2017a), and are associated with marked personal
and societal economic losses due to healthcare costs for mental
and comorbid physical healthcare, reduced productivity in the
workplace, and years of life lost (Alonso 2011; Greenberg 2015). One
meta-analysis of data from 35 countries found a 52% increased risk
of mortality in people with depression (Cuijpers 2014).
Non-communicable diseases
Non-communicable diseases (NCDs) are chronic diseases caused
by a combination of genetic physiological, environmental, and
behavioural factors. The four most common physical NCDs are
cardiovascular disease (CVD), cancer, chronic respiratory diseases,
and type 2 diabetes (WHO 2017a). According to the World Health
Organization (WHO), 41 million people die annually due to NCDs,
corresponding to 71% of all deaths worldwide. NCDs affect people
of all age groups, with 15 million occurring between the ages
of 30 and 69 years (WHO 2017a). Despite the resurgence of
certain infectious diseases, such as tuberculosis and dengue,
and outbreaks of new infectious diseases such as COVID-19,
the global burden of infectious disease overall is decreasing (or
becoming more stagnant in some countries), and being replaced
by an increased burden of disease for NCDs, as well as common
mental disorders (Vos 2017). NCDs decrease patients' health-
related quality of life substantially (Dyer 2010; Solli 2010).
Comorbidity of depressive disorders in people with non-
communicable diseases
NCDs commonly occur with depressive disorders (Patel 2015).
There is a complex association between depression and NCDs (Ngo
2013). Co-existence of depression with an NCD worsens outcomes
for both conditions and is associated with poorer self-management
and treatment adherence, reduced treatment response, and higher
morbidity and mortality for both the mental and the physical
disorder (NICE 2009). NCDs and mental disorders are associated
with similar behavioural factors, such as tobacco use, a less
nutritious diet, physical inactivity, and harmful alcohol use (Stein
2019). Pathophysiological factors, such as increased cytokine levels
or other inflammatory markers associated with NCDs, may increase
the risk of developing depression and worsen symptoms (Katon
2003).
CVD is the leading cause of death globally (Roth 2017). Comorbid
depression is common in people with CVD (approximately 15%) and
the prevalence of depression in people with CVD is higher than in
the general population (Hare 2014). Increased levels of depression
in postmyocardial infarction (heart attack) patients are associated
with a two- to three-fold increased risk of impaired outcomes
within 24 months of the event (Meijer 2011). The association
between depression and CVD risk factors is bidirectional (Pan
2012). Depression is thought to be a risk factor for CVD through
a combination of behavioural (smoking, alcohol intake, physical
inactivity, and obesity) and biological components (affecting
the nervous system, hormone secretion, immune system, and
cardiovascular functions) (Dhar 2016).
Prevalence estimates of major depression (15%), minor depression
(20%), and anxiety disorders (10%) in people treated for cancer are
more than double that observed in the general population (Pitman
2018). Two-thirds of people with cancer and depression also have
clinically significant anxiety symptoms. Figures vary by cancer type
and it is suggested that this is due to the differing prognoses, pain
levels, and degrees of body image disruption associated with each
tumour type, as well as specific tumour-related neuropsychiatric
effects and treatment-related neuropsychiatric adverse effects
(Pitman 2018).
Mental health problems are approximately three times more
prevalent among people with chronic obstructive pulmonary
disease (COPD) than in the general population. Up to 55% of people
with COPD also have anxiety and depression (Laurin 2012). People
with COPD show increased levels of psychological distress, which
in turn leads to higher exacerbation rates. For asthma, mortality
rates in the UK have been found to be twice as high for those also
experiencing depression (Walters 2011).
It is estimated that depression occurs in 13% to 18% of people with
diabetes, which worsens glycaemic control and is associated with
increased complications. Mild depression is thought to oNen go
undiagnosed in people with diabetes because many of the somatic
symptoms are similar (Hermanns 2013).
Description of the intervention
Pharmacological and psychological interventions, alone or in
combination, are recommended in clinical guidelines for the
treatment of mild-to-moderate depression. Behavioural activation
is one of the recommended therapies for treatment of depression
in adults, but is not currently recommended for the treatment
Behavioural activation therapy for depression in adults with non-communicable diseases (Review)
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of moderate-to-severe symptoms of depression in people with
chronic physical health problems (NICE 2009).
Antidepressants are a standard treatment for moderate-
to-severe depression in healthcare settings, whereas for
subthreshold depressive symptoms or mild depression, low-
intensity psychosocial therapy and psychological therapies are
recommended (NICE 2009). While antidepressants are proven to be
effective for the acute treatment of depression for some people,
non-adherence to antidepressant medication is very common
(Hunot 2007; Ten Doesschate 2009; Van Geffen 2009), and is
associated with relapse and recurrence of depression, hospital
visits and hospitalisation, worsening of depression symptoms,
and a lower likelihood of recovery (Gardarsdottir 2009; Ho 2016).
Non-adherence is related to many factors, including concerns
about possible adverse effects of antidepressants, dependence,
and experience of withdrawal symptoms (Davies 2018; Fawzi 2012;
Hunot 2007; Sansone 2012). Studies of treatment for psychiatric
disorders, including depression, consistently report that people
prefer psychological treatment to medication (Churchill 2000;
McHugh 2013; Riedel-Heller 2005).
There is a wide range of psychological therapies available for the
treatment of depressive disorders. Psychological therapies may
be categorised into four philosophical and theoretical schools of
thought, comprising psychoanalytic/dynamic (Freud 1949; Jung
1963; Klein 1960), behavioural (Skinner 1953; Watson 1924; Wolpe
1958), humanistic (Maslow 1943; May 1961; Rogers 1951), and
cognitive approaches (Beck 1979; Lazarus 1971). Each school of
thought incorporates different and overlapping psychotherapeutic
approaches.
Behavioural activation stems from a behavioural psychotherapy
approach first developed in the 1970s by Lewisohn and colleagues
(Dimidjian 2011). It is based on the concept that depression results
from deprivation of positive reinforcement, and the treatment
focuses on identifying and scheduling pleasurable activities, thus
increasing contact with sources of positive reinforcement (Kanter
2012).
When cognitive behavioural therapy (CBT) was developed and
disseminated, behavioural therapy approaches based purely on
operant (learning from the consequences of behaviours) and
respondent (responsive behaviour as a result of a stimulus)
principles were thought insufficient. However, the interest in the
feasibility of behavioural treatments for depression has since been
renewed (Dimidjian 2011; Ekers 2014; Hopko 2003). Jacobson
showed that the behavioural component of CBT was as effective
as the full package of CBT, and investigators developed a new and
more comprehensive model of behavioural activation that would
be amenable to dissemination (Jacobson 1996; Jacobson 2001).
How the intervention might work
Skinner proposed that depression was associated with an
interruption in established sequences of healthy behaviour that
were previously positively reinforced by the social environment
and were based on operant conditioning principles (in which
behaviour patterns are learnt, rather than instinctive) (Skinner
1953). In subsequent expansions of this model, reduction of
positively reinforced healthy behaviours has also been attributed to
a decrease in the number and range of reinforcing stimuli available
to the individual, lack of skill in obtaining positive reinforcement
(Lewinsohn 1974), increased frequency of punishment, or a
combination of these (Lewinsohn 1984).
Behavioural activation can be defined as a brief psychotherapeutic
approach that seeks to change the way a person interacts with their
environment, aiming to:
1. increase access to positive reinforcers of healthy behaviours;
2. reduce avoidance behaviours that limit access to positive
reinforcement;
3. understand and address barriers to activation.
Treatments are collaborative and focused on the present. Many
differing techniques are incorporated into treatment; however, all
use self-monitoring of a mood-environment link and scheduling
of new or adaptive behaviours to meet targets (Kanter 2012). In
doing so, the therapy helps people to make contact with potentially
reinforcing experiences (Jacobson 2001).
The original model of behavioural activation, developed by
Jacobson, was defined primarily by the elimination of cognitive
intervention elements (Dimidjian 2006). On the basis of its original
design, behavioural activation model components commonly
include developing a shared treatment rationale; increasing
access to meaningful events, activities, and consequences; activity
scheduling; developing social skills; and self-monitoring links
between behaviour and mood. In some cases, the use of some form
of problem solving or functional analysis is added to understand,
consider, and overcome any potential barriers to the scheduling of
activities. In contrast to CBT, no attempt is made to directly change
cognitions. However, behavioural activation commonly involves
an exploration of how cognitive processes, such as rumination,
can limit access to behaviours and events which give positive
reinforcement, for example in stopping people with depression
from meeting up with friends or participating in physical exercise
(Kanter 2012; Veale 2008).
It is thought that behavioural activation could be effective in
the treatment of people with depression and comorbid NCDs by
supporting people to identify activities they would like to engage
in and reintroducing valued activities that they have stopped
doing. Positive reinforcement from valued activities through self-
monitoring, activity scheduling, and functional analysis helps to
break the cycle of limiting activities and depressive symptoms.
Why it is important to do this review
According to the clinical guidelines produced by the National
Institute for Health and Care Excellence (NICE), behavioural
activation is one of the recommended treatment options for
subthreshold depressive symptoms, mild-to-moderate depression,
and severe depression, along with CBT and interpersonal
therapy. However, the guidelines acknowledge that evidence
for behavioural activation is less robust than for the other
recommended therapies (NICE 2009). Behavioural activation is
currently not recommended for the treatment of depression in
people with NCDs.
Behavioural activation is increasingly receiving attention as
a potentially cost-effective intervention for common mental
disorders, including for populations with comorbid NCDs, and it
may be delivered and implemented in settings with low resources
or where the demand is greater than the availability of mental
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health practitioners to deliver more complex treatments (Richards
2016). A recent Cochrane Review of behavioural activation
for adults with depression showed low- to moderate-certainty
evidence that behavioural activation is as effective as most other
psychological therapies and more effective than most non-active
comparators (Uphoff 2020). To allow for meaningful meta-analyses
in a relatively homogeneous patient population, people with
comorbidities were excluded from the review. The current review
will fill this gap in the literature by specifically addressing the
population of people with depression and comorbid NCDs.
O B J E C T I V E S
1. To examine the effects of behavioural activation compared with
any control group for the treatment of depression in adults with
non-communicable diseases (NCDs).
2. To examine the effects of behavioural activation compared with
each control group separately (no treatment, waiting list, other
psychological therapy, pharmacological treatment, or any other
type of treatment as usual) for the treatment of depression in adults
with NCDs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For consistency and to facilitate interpretation of the results of this
review in the wider context of evidence on behavioural activation
for depression, we followed methods described in the published
protocol 'Behavioural activation therapies for depression in adults'
where possible (Uphoff 2020).
Randomised controlled trials (RCTs) were eligible for inclusion in
this review. We included trials employing a cross-over design (while
we acknowledge that this design is rarely used in psychological
therapy trials), but we only used data from the first active treatment
phase. Cluster-RCTs and pilot RCTs were also eligible for inclusion.
Quasi-RCTs, in which treatment assignment is decided through




Trials with adults (aged 18 years and over) of any sex or gender were
eligible for inclusion. We excluded trials with participants under 18
years of age. If a trial included both adults and children, we planned
to contact authors to request data for adults only. If these data were
not available, we planned to exclude the trial. Participants had to
have depression (mild, moderate, or severe) with a comorbid NCD.
We included studies on the four NCDs most prevalent worldwide:
CVD, cancer, chronic respiratory disease, and type 2 diabetes.
Postnatal depression is considered a separate condition with
contributing factors distinct from major depressive disorder, and
we, therefore, excluded participants with this condition.
Setting
Trials could be conducted in a primary, secondary, specialist, or
community setting.
We excluded trials involving inpatients, as these represent settings
that differ with regards to the complexity of patients' healthcare
needs, the way patients access care, and the way in which
interventions are delivered and embedded in clinical practice. The
same intervention may lead to different results in inpatient settings
compared to other settings, and we would not be able to ascertain
whether this would be a result of the type of participants, the
delivery of the intervention, or features of the setting itself. If a
trial included both inpatients and outpatient settings, we planned
to contact authors to request data for participants eligible for
inclusion in our review only. If these data were not available, we
planned to exclude the trial.
Nursing homes in this review were considered outpatient settings,
as they are places of residence. Hospice care is considered
specialised medical care and we, therefore, excluded studies
conducted with participants in a hospice.
We included trials that focus on specific populations – nurses,
carers, participants at a specific workplace with depression – if all
participants met the criteria for depression.
Studies from all countries were eligible for inclusion.
Diagnosis
We included trials that focussed on acute phase treatment of
clinically diagnosed depression in people with comorbid NCDs
(CVD, cancer, chronic respiratory disease, and type 2 diabetes).
Trials adopting any standardised diagnostic criteria to define
participants experiencing an acute phase unipolar depressive
disorder were included. Accepted diagnostic criteria include
Feighner criteria, Research Diagnostic Criteria, and criteria of
the Diagnostic and Statistical Manual of Mental Disorders, Third
Edition (DSM-III; APA 1980), DSM-III-Revised (APA 1987), DSM-Fourth
Edition (DSM-IV; APA 1994), DSM-IV-Text Revision (APA 2000), DSM-
Fi#h Edition (DSM-5; APA 2013), and International Classification of
Diseases, Tenth Edition (ICD-10; WHO 1992).
Earlier trials may have used ICD-Ninth Edition (ICD-9; WHO 1978),
but ICD-9 is not based on operationalised criteria, so we excluded
trials using ICD-9 to diagnose depression. We also excluded
studies of participants with subthreshold depression, symptoms
of depression without a formal diagnosis, or a diagnosis based on
symptom scales such as Becks Depression Inventory or Hamilton
Rating Scale for Depression (HRSD).
We included studies of participants diagnosed with anxiety, or with
symptoms of anxiety, if they were also diagnosed with depression.
Types of interventions
Experimental interventions
Previously published Cochrane Reviews for treatment of
depression provided a framework for psychological therapies
including behavioural therapy (Churchill 2013; Hunot 2013;
Shinohara 2013). Given recent developments in literature
and practice regarding behavioural activation approaches, we
considered behavioural activation to be part of behavioural
therapies, rather than being classified as a 'third wave' therapy.
In line with the behavioural therapy for depression review (Uphoff
2020), we created the comparator categories of psychological
therapies on the basis of both treatment approach (e.g. their
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theoretical background and the manuals used) and content (e.g.
therapeutic techniques employed) (Appendix 1).
Behavioural activation
We included trials evaluating treatment approaches for depression
and anxiety that were either explicitly called 'behavioural
activation', or treatments that were described using the main
elements of behavioural activation for depression, such as pleasant
or rewarding events and activities, activity scheduling, positive
reinforcement from the environment, and positive interaction or re-
engagement with the environment. Interventions that contained
some elements of behavioural therapy and elements of other
approaches, such as CBT or problem-solving therapy, were not
eligible for inclusion.
Format of psychological therapies
Therapies delivered by therapists of all levels were eligible
for inclusion. This included psychologists or psychotherapists
accredited by a professional body for psychology or psychotherapy,
who completed formal training to deliver psychological therapies,
as well as lay counsellors and non-specialist therapists who had
been specifically trained to deliver treatment according to a
behavioural activation protocol.
We included computerised and self-help interventions if they were
facilitated by a therapist. This means at least some element of
interaction with a therapist was required.
Psychological therapies conducted on an individual or group basis
were eligible for inclusion.
The number of sessions was not limited, and we accepted
psychological therapies delivered in only one session.
Comparators
All comparators were accepted if they were not a type of
behavioural activation. We categorised psychological therapies as
behavioural therapy, social skills training/assertiveness training,
relaxation therapy, CBT, third-wave CBT, psychodynamic, and
humanistic and integrative approaches.
Behavioural therapy
We planned to include any behavioural therapies that did
not contain the main elements of behavioural activation as
comparators.
Social skills training/assertiveness training
The social skills training model proposes that depressed
people may have difficulty initiating, maintaining, and ending
conversations (Jackson 1985). Because of these deficits, the
individual is unable to elicit mutually reinforcing behaviour from
other people in his or her environment. Social skills training
subsumes assertion and conversational skills, together with more
specialised subskills, such as dating and job interview skills.
Different social contexts may be targeted, for example interaction
with friends, family members, people at school, or at work, and
interventions such as instruction, modelling, rehearsal, feedback,
and reinforcement are used to enable the development of new
responses (Jackson 1985). As assertiveness training represents
a key component of social skills training, we included it in this
category.
Relaxation therapy
Relaxation training is a behavioural stress management technique
that induces a relaxation response, helping to switch off the
fight/flight response and causing levels of stress hormones in the
bloodstream to fall. A variety of techniques may be used to induce
relaxation, the most common of which is Jacobson's progressive
muscle relaxation training (Bernstein 1973).
Cognitive behavioural therapies
In CBT, therapists aim to work together with people receiving
treatment to understand the link between thoughts, feelings,
and behaviours, and to identify and modify unhelpful thinking
patterns and underlying assumptions about the self, others, and
the world (Beck 1979). Cognitive change methods for depression
are targeted at the automatic thought level in the first instance
and include thought catching, reality testing, and task assigning
as well as generating alternative strategies (Williams 1997).
Behavioural experiments are then used to re-evaluate underlying
beliefs and assumptions (Bennett-Levy 2004).  We categorised
these therapies into six subcategories: cognitive therapy, rational
emotive behaviour therapy, problem-solving therapy, self-control
therapy, a coping with depression course, and other CBTs.
Third-wave cognitive and behavioural therapies
Third-wave CBT approaches have been developed more recently
and now exist alongside established therapies such as CBT.
Rather than focusing on the contents of thoughts, these therapies
tend to focus on the process and functions of thoughts and
an individual's relationship with thoughts and emotions. This
may include suppressing or avoidance of emotions, thoughts,
and bodily sensations (Hofmann 2008). Third-wave approaches
use strategies relating to mindfulness, emotions, acceptance,
relationships, values, goals, and understanding the thinking
process, to bring about changes in thinking (Hayes 2006). Drawing
from psychodynamic and humanistic principles, third-wave CBT
approaches place great emphasis on use of the therapeutic
relationship. We categorised these therapies into subcategories:
acceptance and commitment therapy, compassionate mind
training, functional analytic psychotherapy, metacognitive therapy,
mindfulness-based cognitive therapy, dialectical behaviour
therapy, and other third-wave CBTs.
Cognitive behavioural therapy bibliotherapy
When someone with depression does not have access to a qualified
therapist or CBT practitioner they may seek therapy through the
use of self-help materials incorporating a CBT approach (Anderson
2005).
Psychodynamic therapies
Grounded in psychoanalytic theory (Freud 1949), psychodynamic
therapy uses the therapeutic relationship to explore and resolve
unconscious conflict through transference (projection of feelings
on to the therapist) and interpretation, with development of insight
and character change (within certain boundaries) as therapeutic
goals, and relief of symptoms as an indirect outcome. Brief therapy
models have been devised by Malan 1963, Mann 1973, and Strupp
1984. We categorised these therapies into four subcategories: drive/
structural model (Freud 1949), relational model (Luborsky 1998;
Strupp 1984), integrative analytic model (Mann 1973), and other
psychodynamic therapies.
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Humanistic therapies
Contemporary models of humanistic therapies differ from
one another somewhat in clinical approach, but all focus
attention on the therapeutic relationship (Cain 2002), within
which therapist 'core conditions' of empathy, genuineness,
and unconditional acceptance and support (positive regard)
(Rogers 1951), are regarded as cornerstones for facilitating
client insight and change.  We categorised these therapies into
seven subcategories:  person-centred therapy (Rogerian), gestalt
therapy, experiential therapies, transactional analysis, existential
therapy, non-directive/supportive therapies, and other humanistic
therapies.
Interpersonal, cognitive analytic, and other integrative therapies
Integrative therapies are approaches that combine components
of different psychological therapy models. Integrative therapy
models include interpersonal therapy (Klerman 1984), cognitive
analytic therapy (Ryle 1990), and Hobson's conversational model
(Hobson 1985), manualised as psychodynamic interpersonal
therapy (Shapiro 1990). With its focus on the interpersonal
context, interpersonal therapy was developed to specify what
was thought to be a set of helpful procedures commonly used
in psychotherapy for depressed outpatients (Weissman 2007),
drawing in part from attachment theory (Bowlby 1980), and
CBT within a set timeframe (time-limited). Cognitive analytic
therapy, also devised as a time-limited psychotherapy, integrates
components from cognitive and psychodynamic approaches. The
conversational model integrates psychodynamic, interpersonal,
and person-centred model components.
Counselling interventions traditionally draw from a wide range
of psychological therapy models, including person-centred,
psychodynamic and cognitive behavioural approaches, applied
in combination, according to the theoretical orientation of
practitioners (Stiles 2008). Therefore, we will usually include
trials of counselling with integrative therapies. However, if
the counselling intervention consisted of a single discrete
psychological therapy approach, we categorised it as such, even if
the intervention was referred to as 'counselling'. If the intervention
is manualised, this would inform our classification.
Motivational interviewing and other forms of integrative therapy
approaches are also included in this category.
Waiting list
Participants are randomly assigned to the active intervention group
or control group, and they will either receive the intervention first or
be assigned to a waiting list until all participants in the intervention
group have received the intervention. During the trial, people on
the waiting list can receive any appropriate medical care.
Attention placebo
We defined this as a control condition that is regarded as inactive
by both researchers and participants in a trial.
Psychological placebo
We define this as a control condition in a trial that is regarded by
researchers as inactive but is regarded by participants as active
(also called placebo therapy or sham treatment).
Medication
All medication prescribed with the goal to treat depression, most
commonly antidepressants; any dose, route of administration,
duration, and frequency.
Medical placebo
All types of medical placebos or 'sugar pills'.
No treatment
Trial participants not receiving any treatment for depression during
the trial.
Treatment as usual
Treatment as usual, standard care, or usual care would be
any appropriate medical care during the study. This may, for
example, involve monitoring of the person receiving treatment,
regular check-ups, no treatment, or any type of treatment. What
constitutes treatment as usual will depend on the setting and
healthcare system in which the study was conducted. If a study
arm fitted clearly in any of the above categories, for example, 'no
treatment' or a type of psychological therapy, we categorised it as
such.
Excluded interventions
We excluded trials of long-term continuation or maintenance
therapy interventions designed to prevent relapse of depression
or to treat chronic depressive disorders from this review. Similarly,
we excluded trials of interventions designed to prevent a future
episode of depression.
We excluded psychological therapy models based on social
constructionist principles (that focus on the ways in which
individuals and groups participate in the construction of their
perceived social reality), including couples therapy (Jacobson
1993), family therapy (Crane 2002), solution-focused therapy (de
Shazer 1988), narrative therapy (White 1990), personal construct
therapy (Kelly 1955), neurolinguistic programming (Bandler 1982),
and brief problem solving (Watzlavick 1974). These therapies
work with patterns and dynamics of relating within and between
family, social, and cultural systems to create a socially constructed
framework of ideas (O'Connell 2007), rather than focusing on
individuals' reality. A previously published Cochrane Review on
couples therapy for depression has been updated (Barbato 2018),
and a review of family therapy for depression is to be updated
(Henken 2007).
Types of outcome measures
Primary outcomes
1. Treatment efficacy for depression: the number of participants
who responded to treatment, as determined by changes
in scores for Beck Depression Inventory (BDI; Beck 1961),
Hamilton Rating Scale for Depression (HAM-D/HRSD; Hamilton
1960), or Montgomery-Asberg Depression Rating Scale (MADRS;
Montgomery 1979), or in scores from any other validated
depression scale. We used HAM-D, and, if this was not available,
we used MADRS, and if MADRS was not available, then we
used BDI. If BDI was not available, we used the measure
most frequently used across trials. Many trials define response
as 50% or greater reduction on BDI, HAM-D, etc., with some
trials defining response using Jacobson's Reliable Change
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Index (Jacobson 1992); we accepted the trial authors' original
definition and preferred Jacobson's Reliable Change Index if this
was used in addition to other response outcomes.
2. Treatment acceptability: the number of participants who
dropped out of the study aNer being randomised and allocated
to a study arm.
Secondary outcomes
1. Improvement in depression symptoms, based on a continuous
outcome of group mean scores at the end of treatment. If
multiple measures had been used for this outcome within one
trial, we adopted the same hierarchy used for the primary
outcome 'treatment efficacy for depression'.
2. Quality of life, assessed with validated measures such as the 36-
item Short Form (SF-36) (Ware 1993), EQ-5D (EuroQol; Brooks
1995), and World Health Organization Quality of Life (WHOQOL;
WHOQOL 1998).
3. Social adjustment and functioning, including Global
Assessment of Function scores (Luborsky 1962).
4. Improvement in anxiety symptoms, measured using a validated
continuous scale, either assessor-rated, such as the Hamilton
Anxiety Scale (HAM-A; Hamilton 1959), or self-report, including
the Trait subscale of the Spielberger State-Trait Anxiety
Inventory (STAI-T; Spielberger 1983), and the Beck Anxiety
Inventory (BAI; Beck 1988). We used HAM-A, and if this was
not available, we used STAI-T, and if this was not available, we
used BAI. If BAI was not available, we used the measure most
frequently used across trials.
5. Adverse effects, such as counts of completed suicides,
attempted suicides, or worsening of symptoms were
summarised in narrative form.
Search methods for identification of studies
Electronic searches
Searches were developed for the concepts: Behavioural Activation,
Depression, Chronic Respiratory Diseases, Type 2 Diabetes,
Cardiovascular Diseases (including Stroke) and Cancer. Subject
headings and free-text words were identified for use from previous
systematic reviews (Hooper 2018; Uphoff 2020; Usmani 2017),
the Information Specialist, and the project team members.
The Cochrane Highly Sensitive Search Strategy for identifying
randomized trials in MEDLINE: sensitivity- and precision-
maximizing version (2008 revision); Ovid format was used in the
MEDLINE strategy. The search was peer-reviewed by an Information
Specialist. See Appendix 2 for full search strategies.
The results of the database searches were stored and deduplicated
in an EndNote library.
We searched the following databases during September and
October 2019.
1. Cochrane Common Mental Disorders Trials Register (CCMD-
CTR), all available years.
2. Cochrane Central Register of Controlled Trials (Wiley): 2019,
Issue 9.
3. (Ovid) MEDLINE(R) and Epub Ahead of Print, In-Process & Other
Non-Indexed Citations and Daily 1946 to 23 September 2019.
4. Embase Classic + Embase (Ovid) 1947 to 24 September 2019.
5. Global Health (Ovid) 1910 to week 36, 2019.
6. African Index Medicus (via WHO Global Health Index Medicus),
all available years.
7. ClinicalTrials.gov (US NIH), all available years.
8. ISMEAR Index Medicus for the South East Asia Region (via WHO
Global Health Index Medicus).
9. LILACS Latin American and Caribbean Health Sciences Literature
(via WHO Global Health Index Medicus), all available years.
10.PsycINFO (Ovid) 1806 to September week 2, 2019.
11.International Clinical Trials Registry Platform (WHO), all
available years.




We searched the following sources of grey literature (primarily for
dissertations and theses) in September 2019.
1. Open Grey (www.opengrey.eu).
2. ProQuest Dissertations & Theses Global (www.proquest.com/
products-services/pqdtglobal.html).
3. DART-Europe E-theses Portal (www.dart-europe.eu).
4. EThOS – the British Libraries e-theses online service
(ethos.bl.uk).
5. Open Access Theses and Dissertations (oatd.org).
Reference lists
We checked the reference lists of included trials and relevant
systematic reviews to identify additional trials missed from the
original electronic searches (e.g. unpublished or in-press citations).
Personal communication
We contacted trial authors and subject experts for information on
unpublished or ongoing trials, or to request additional trial data.
Data collection and analysis
Selection of studies
Two review authors (of EU, RR, DC, MPi, MPu) independently
examined the abstracts of all publications obtained through the
search strategy. We obtained full articles of all trials and two
review authors (of EU, DC, MPi, DB) independently assessed full-
texts according to the criteria relating to characteristics of the
studies, participants, and interventions. We discussed reasons for
disagreement with a third review author (of EU, RC, NS, DE) and
contacted external experts or trial authors if necessary in order
to reach agreement. We recorded reasons for excluding records at
this stage in the Characteristics of excluded studies table. For all
included studies, we linked multiple reports from the same study.
We constructed a PRISMA flow diagram to show the process of study
selection (Moher 2009).
Data extraction and management
Two review authors (of EU, PM, DB) independently extracted
data from each trial. These review authors discussed any
disagreements with an additional review author (of EU, MPi, NS),
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and, when necessary, contacted the authors of the trials for further
information.
We extracted and entered data regarding study characteristics,
methods, intervention and comparator, and results into Covidence
data extraction forms.These data extraction forms were piloted by
two authors and amended as a result of piloting.
Management of time points
We summarised and categorised post-treatment outcomes and
outcomes at each reported follow-up point as follows: short term
(up to six months post-treatment), medium term (seven to 12
months post-treatment) and long term (longer than 12 months).
Assessment of risk of bias in included studies
Two review authors (of EU, PM, DB) independently assessed the risk
of bias in selected trials and discussed any disagreements with a
third review author (of EU, MPi, NS). Where necessary, we contacted
trial authors for further information. We presented all 'Risk of bias'
data graphically, and narratively in the text. We planned to use
allocation concealment as a marker of trial quality for the purpose
of undertaking sensitivity analyses, but these sensitivity analyses
were not conducted due to a lack of available data (Differences
between protocol and review).
We assessed risk of bias for each included trial using the Cochrane
'Risk of bias' tool (version 1) (Higgins 2016), which considers the
following domains.
1. Risk of bias arising from the randomisation process, including
allocation and randomisation.
2. Risk of bias due to deviations from the intended interventions,
including blinding of participants and people delivering the
interventions.
3. Missing outcome data.
4. Risk of bias in measurement of the outcome, including blinding
of outcome assessors.
5. Selective outcome reporting.
6. Other sources of bias.
For cluster-RCTs and cross-over trials, we planned to use the
templates specifically designed to assess these types of trials, with
the same domains. However, no such trials were included.
In the 'Other sources of bias' domain, we considered any additional
problems with bias, including the following issues relevant to
psychological therapy trials.
1. Treatment fidelity: was the therapy monitored against a manual
or a scale through audiotapes or videotapes?
2. Researcher allegiance/conflict of interest: did the researcher
have a vested interest for or against the therapies under
examination?
3. Therapist allegiance/conflict of interest: did the therapist have a
vested interest for or against the therapies provided?
Measures of treatment effect
Continuous outcomes
Where trials used the same outcome measure for comparison, we
pooled data by calculating the mean difference (MD). If trials used
different measures to assess the same outcome, we planned to
pool data with standardised mean difference (SMD) and calculate
95% confidence intervals (CIs). However, studies reported the same
outcome measure for all meta-analyses therefore we did not use
SMDs.
An SMD or MD of zero means that the intervention and control
groups have equivalent treatment effects. We anticipated that, for
most measures, a lower score would indicate greater improvement.
For example, a lower score on depression symptom instruments
indicates an improvement in symptoms. In these cases, an SMD or
MD less than zero indicates that the intervention has a greater effect
than the control. An SMD or MD greater than zero indicates that the
intervention has a smaller effect than the control. Interpretation of
the SMD or MD is reversed in cases where a greater continuous score
indicates greater improvement.
Dichotomous outcomes
We analysed dichotomous outcomes by calculating a pooled risk
ratio (RR) and 95% CIs for each comparison.
In addition, we calculated the number needed to treat for
an additional beneficial outcome (NNTB) with 95% CIs for all
dichotomous outcomes to facilitate interpretation; this is the
expected number of people who need to receive the intervention
rather than the comparator for one additional person to achieve a
beneficial outcome (Schünemann 2017).
If one trial uses both continuous and dichotomous variables for the
same outcome, we gave preference to the continuous outcome.
Unit of analysis issues
Cluster-randomised trials
We included cluster-randomised trials if proper adjustment for the
intracluster correlation could be conducted in accordance with the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a).
Cross-over trials
If included trials employed a cross-over design in the review, we
only used data from the first active treatment phase.
Trials with multiple treatment groups
Multiple-arm trials (those with more than two intervention arms)
can pose analytical problems in pair-wise meta-analysis. For trials
with more than two relevant active treatment arms, we managed
data in this review as follows.
Dichotomous data
We collapsed data from relevant active intervention arms into a
single arm for comparison, or we split data from relevant active
intervention arms equally between comparator arms (Higgins
2011b).
Dealing with missing data
We managed missing dichotomous data through intention-to-
treat (ITT) analysis, in which we assumed that participants who
dropped out aNer randomisation had a negative outcome. We
also conducted best/worse-case scenarios for the clinical response
outcome, in which we assumed that dropouts in the active
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treatment group had positive outcomes and those in the control
group had negative outcomes (best-case scenario), and that
dropouts in the active treatment group had negative outcomes
and those in the control group had positive outcomes (worst-case
scenario), thus providing boundaries for the observed treatment
effect.
We analysed missing continuous data on an endpoint basis,
including only participants with a final assessment, or by using the
last observation carried forward (LOCF) to the final assessment,
if trial authors reported LOCF data. If standard deviations (SDs)
were missing, we attempted to obtain these data by contacting
trial authors. When SDs were not available from trial authors, we
planned to calculate them from P values, t values, CIs, or standard
errors, if these were reported in the articles (Deeks 1997).
If a vast majority of SDs were available and only a minority of SDs
were unavailable or unobtainable, we planned to use the method
devised by Furukawa and colleagues to impute SDs and calculate
percentage responders (da Costa 2012; Furukawa 2005; Furukawa
2006).
No SDs were missing in the included studies and these methods
were, therefore, not used.
Assessment of heterogeneity
We assessed statistical heterogeneity using the Chi2 test, which
provides evidence of variation in effect estimates beyond that
of chance. Because the Chi2 test has low power to assess
heterogeneity when a small number of participants or trials are
included, we conservatively set the P value at 0.1 (Deeks 2017). We
also quantified heterogeneity using the I2 statistic, which calculates
the percentage of variability due to heterogeneity rather than to
chance (Higgins 2003). We considered I2 statistic values in the range
of 50% to 90% to represent substantial statistical heterogeneity and
explored them further. The importance of the observed I2 statistic
depends on the magnitude and direction of treatment effects and
the strength of evidence for heterogeneity. Forest plots generated in
Review Manager 5 (Review Manager 2014) provided an estimate of
Tau2, the between-trial variance in a random-effects meta-analysis
(Deeks 2017).
Assessment of reporting biases
As far as possible, we minimised the impact of reporting biases
by undertaking comprehensive searches of multiple sources
(including trials registries), to identify unpublished material and
including non-English language publications.
We tried to identify outcome reporting bias in trials by recording all
trial outcomes, planned and reported, and noting where outcomes
were missing. If we found evidence of missing outcomes, we
attempted to obtain any available data directly from the trial
authors.
We planned to construct funnel plots to establish the potential
influence of reporting biases and small-trial effects (Sterne 2017).
However, no funnel plots were constructed due to the small number
of included studies.
Data synthesis
We conducted meta-analyses of included trials. Given the potential
heterogeneity of behavioural activation approaches for inclusion,
together with the likelihood of differing secondary comorbid
mental disorders and different NCDs in the population of interest,
we decided a-priori to use a random-effects model in all analyses.
Subgroup analysis and investigation of heterogeneity
Clinical heterogeneity
We planned to conduct the following subgroup analyses for
primary outcomes treatment efficacy and treatment acceptability,
for the main comparison 'behavioural activation versus any control
group'.
1. Country: subgroup analyses with studies conducted in high-
income countries and studies conducted in low- and middle-
income countries, to account for heterogeneity due to study
setting. Countries were grouped according to the World Bank
income classification (World Bank 2019).
2. Level of therapist: analyses for specialist (qualified or accredited
mental health specialist with substantial training), non-
specialist (short training, lay workers, or primary care workers)
therapists, or specialist in training (e.g. several years of
training in psychotherapy or mental health nursing). Although
psychotherapy has traditionally been delivered by mental
health specialists, the effectiveness of behavioural activation
delivered by non-specialists is of great interest in settings
where the demand for mental health treatments outweighs
the availability of treatments, such as low- and middle-income
countries.
3. Type of NCD: CVD, cancer, chronic respiratory disease, and
type 2 diabetes. We expected that these different NCDs might
affect mental health differently, and factors associated with
these diseases might influence success of behavioural activation
therapy.
However, it was not possible to conduct these subgroup analyses
due to the limited availability of data.
Sensitivity analysis
The following sensitivity analyses were planned for primary
outcomes treatment efficacy and treatment acceptability, for the
main comparison 'behavioural activation versus any control group'.
1. Trial quality: we would exclude low-quality trials in a sensitivity
analysis, if we identified several higher-quality trials. As a marker
of quality, we would have used the 'allocation concealment'
criteria from the 'Risk of bias' assessment.
2. Mode of delivery: we would have excluded therapies delivered
through computer-based or electronic guidance without a
substantial face-to-face component.
3. Group therapy: we would have excluded trials of group
therapy for behavioural activation as the mode of delivery of
psychotherapy could influence effectiveness of the therapy.
However, it was not possible to conduct these sensitivity analyses
due to the limited availability of data.
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Summary of findings and assessment of the certainty of the
evidence
We constructed a 'Summary of findings' table to present the main
findings of the review. We reported the outcomes listed below
and presented standardised effect size estimates and 95% CIs. We
used GRADEpro GDT to create our 'Summary of findings' table
(GRADEpro GDT), and followed standard methods as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2011).
In line with our first objective, the comparison included in the
'Summary of findings' table was behavioural activation versus any
control group.
We included the following outcomes (measured up to 24 months)
in the 'Summary of findings' table.
1. Treatment efficacy for depression (number of participants
responding to treatment).
2. Treatment acceptability (number of participants who dropped
out).
3. Improvement in depression symptoms as a continuous score.
4. Quality of life.
5. Social adjustment and functioning score.
6. Improvement in anxiety symptoms as a continuous score.
We created the 'Summary of findings' table before writing our
discussion, abstract, and conclusions, so that the review authors
could jointly consider the potential impact of the certainty of the
evidence for each outcome on the mean treatment effect and our
confidence in these findings. Our confidence in the mean treatment
effects based on the GRADE assessments was then reflected in
the interpretation of the results, which informed the abstract, lay
summary, and discussion sections of the review.
R E S U L T S
Description of studies
Results of the search
The database searches identified 6066 records. Once 2140
duplicates were removed there were 3926 records (Figure 1). ANer
excluding 3813 irrelevant records, we assessed 113 records for
eligibility and included two studies (10 records) in this review.
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Figure 1.   Study flow diagram. NCD: non-communicable disease; RCT: randomised controlled trial.
 
Included studies
The two included studies were both RCTs and evaluated the Living
Well with Stroke intervention (Mitchell 2009) and brief behavioural
activation for women with breast cancer (Hopko 2011). Together
these studies included 181 participants. We contacted authors for
information needed to complete data extraction and risk of bias
assessments. The author of one study responded to our request
(Mitchell 2009).
Setting
Both studies were conducted in the US, and participants were
recruited in the hospital. In one study, participants were within
four months poststroke (Mitchell 2009), while in the other study
participants were receiving treatment for breast cancer (Hopko
2011).
Participants
Participants in the study by Mitchell and colleagues had a mix of
gender, age, and ethnicity (Mitchell 2009), while participants in the
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study by Hopko and colleagues were all women, with a mean age
of 55 years, and mostly White American (Hopko 2011). Employment
status varied.
One study did not report comorbidities in mental health (Mitchell
2009), while in the other study, 55/80 participants (69%) had
depression and an anxiety disorder (Hopko 2011).
Depression severity was very similar, with a mean score of around
20 on the HRSD in both studies. In the study by Hopko and
colleagues all participants had a moderate level of depression
(Hopko 2011), while in the study by Mitchell and colleagues,
some participants had moderate and others severe depression
symptoms (Mitchell 2009).
Intervention
In both studies, behavioural activation was the main component
of the intervention, and weekly sessions were delivered in an
individual face-to-face format for eight weeks. One study used
a mental health specialist to deliver the intervention (Mitchell
2009), while the other used clinical psychology doctoral students
(specialists in training) (Hopko 2011).
Comparator
Comparators in both studies were similar in duration to
the behavioural activation intervention. One study compared
behavioural activation with an antidepressant (sertraline in the
first instance) versus treatment as usual with an antidepressant
(Mitchell 2009). Treatment as usual in this case primarily involved
the provision of medical care aNer stroke. The other study used
problem-solving therapy as a comparator, which was delivered
with the same intensity and format as the behavioural activation
intervention (Hopko 2011).
Outcomes
Both studies reported our prespecified primary outcomes,
treatment efficacy and treatment acceptability (dropouts). Both
studies used the HRSD to measure treatment efficacy, as indicated
by remission of depression, and to measure and report depression
symptoms. Criteria for remission were a score of seven or less on
the HRSD in Hopko 2011 and a score of less than 10 in Mitchell 2009.
Other outcomes, reported by Hopko 2011 only, were physical
functioning measured with the SF-36, quality of life measured using
the Quality Of Life Inventory (QOLI), and anxiety using the BAI.
Neither study reported adverse effects. In one study, adverse effects
were said to be monitored (see Mitchell 2008 under Mitchell 2009).
Both studies reported outcomes directly aNer the end of the
treatment (nine weeks), in the short term (up to six months), and
medium term (at 12 months). Mitchell 2009 also reported long-term
outcomes (24 months).
Excluded studies
ANer obtaining full-text reports, we excluded 93 studies (101 full-
text records) (Figure 1). Of the studies excluded at this stage, for
50 studies behavioural activation was not the intervention or the
main component of the intervention. Seven studies were not RCTs.
We were unable to exclude these studies at the stage of title and
abstract screening because abstracts did not clearly specify the
study design or intervention, or both. These records are not listed
in the review.
Among the 36 studies (44 records) which are listed as Excluded
studies in this review, reasons for exclusion were the lack of a formal
clinical diagnosis of depression (32 studies) and a study population
without one of the NCDs of interest to this review (four studies)
(Characteristics of excluded studies table).
Studies awaiting classification
The full-text manuscript of one study could not be obtained
(NCT02185482; Characteristics of studies awaiting classification
table).
Ongoing studies
One study was ongoing with data collection estimated to finish in
2021 (NCT03688100; Characteristics of ongoing studies table).
Risk of bias in included studies
Allocation
Both studies used a computer programme to randomise
participants, and were therefore at low risk of bias from random
sequence allocation. Allocation concealment was achieved in one
study (Mitchell 2009), while this was unclear for the other study
(Hopko 2011).
Blinding
Both studies were at high risk of performance bias and at low
risk for detection bias. Given the nature of psychological therapy,
blinding of participants and personnel is very uncommon in clinical
trials of this intervention. Outcome assessors were blinded to the
participants' study arm allocation in both studies.
Incomplete outcome data
One study was at high risk of attrition bias, because missing
outcome data for 10/42 participants in the behavioural activation
study arm and 5/38 participants in the problem-solving therapy
arm were imputed (Hopko 2011). Imputing outcome data may
result in bias if data were not missing at random. There is a risk
that attrition may be related to participant satisfaction with the
intervention or allocation. The risk of attrition bias was low for the
other study (Mitchell 2009). Although not all reasons for dropout
were reported, dropout rates were similar in both study arms.
Selective reporting
One paper did not contain a reference to a study protocol or online
trial registration and risk of reporting bias was, therefore, unclear
(Hopko 2011). The authors of the other study referred to an online
registration of the trial protocol, for which reported outcomes
matched those presented in the results paper (Mitchell 2009).
Other potential sources of bias
For both studies, authors of the publication also developed the
behavioural activation intervention and supervised therapists who
delivered the intervention in the trial. These authors are likely
to prefer a study result favouring behavioural activation, and we,
therefore, judged them to be at high risk of 'other bias' due to a
potential conflict of interest.
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Effects of interventions
See: Summary of findings 1 Behavioural activation compared with
any comparator for depression in adults with non-communicable
diseases
We planned to conduct meta-analyses for our prespecified
primary and secondary outcomes (treatment efficacy, treatment
acceptability, depression symptoms, quality of life, social
adjustment and functioning, and anxiety symptoms) for
behavioural activation compared with any control group, and
behavioural activation compared with each control group
separately. However, the inclusion of only two studies meant that
a meta-analysis could only be conducted for short-term treatment
efficacy of behavioural activation compared with any control group
(treatment as usual and problem-solving therapy).
1. Behavioural activation versus any comparator
1.1 Treatment efficacy for depression (remission)
Short-term treatment efficacy appeared to be greater for
behavioural activation than comparators (RR 1.53, 95% CI 0.98 to
2.38). Results from one study showed that this difference between
study arms became less clear in the medium term (RR 1.76, 95% CI
1.01 to 3.08) and long term (RR 1.42, 95% CI 0.91 to 2.23) (Analysis
1.1).
Sensitivity analyses
We conducted sensitivity analyses to investigate the influence
of missing data on the results. These analyses could only be
performed for medium-term results (Analysis 1.7). The different
scenarios included treatment data with an ITT approach, a best-
case scenario, and a worst-case scenario. Treatment efficacy was
greater for behavioural activation than for the comparator (usual
care) in the ITT sensitivity analysis (RR 1.78, 95% CI 1.01 to 3.16; 1
study) and the best-case scenario (RR 2.32, 95% CI 1.34 to 4.03; 1
study), but not in a worst-case scenario (RR 1.29, 95% CI 0.79 to 2.11;
1 study).
1.2 Treatment acceptability (dropouts)
There was no evidence of a difference in the two studies in
treatment acceptability in the short term (RR 1.81, 95% CI 0.68 to
4.82; 1 study) and medium term (RR 0.88, 95% CI 0.25 to 3.10; 1
study) (Analysis 1.2).
1.3 Improvement in depression symptoms
Endpoint and change from baseline data on depression symptoms
have been combined for each time point. There was no evidence
of a difference in depression symptoms between behavioural
activation and comparators in the short term (MD –1.15, 95% CI –
2.71 to 0.41), medium term (MD –1.51, 95% CI –4.14 to 1.12), or long
term (MD –2.00, 95% CI –4.71 to 0.71) (Analysis 1.3).
1.4 Quality of life
One study reported on quality of life and found no evidence of a
difference between study arms in the short term (MD 0.40, 95% CI –
0.16 to 0.96) or in the medium term (MD –0.10, 95% CI –0.74 to 0.54)
(Analysis 1.4; Hopko 2011).
1.5 Social adjustment and functioning
One study reported on the physical component of functioning and
found no evidence of a difference between behavioural activation
and the comparator in the short term (MD 2.70, 95% CI –6.99 to
12.39) and in the medium term (MD 2.20, 95% CI –6.37, 10.77)
(Analysis 1.5; Hopko 2011).
1.6 Improvement in anxiety symptoms
One study reported no evidence of a difference between study arms
in anxiety symptoms in the short term (MD –1.70, 95% CI –4.50 to
1.10) and medium term (–1.70, 95% CI –4.48 to 1.08) (Analysis 1.6;
Hopko 2011).
1.7 Adverse effects
Neither study reported data on adverse effects.
D I S C U S S I O N
Summary of main results
We included results from two RCTs with 181 participants. This
means the conclusions we could draw from this review on
the effectiveness of behavioural activation for the treatment of
depression in adults with NCDs were limited.
Primary outcomes
Low- to moderate-certainty evidence suggested behavioural
activation was more effective than comparator groups (treatment
as usual and problem-solving therapy) in the short term, with
differences between behavioural activation and comparators
becoming less pronounced in the medium term and long term.
Low-certainty evidence suggested there was no difference in
treatment acceptability, measured by participants dropping out of
the study, between behavioural activation and comparators.
The benefit of behavioural activation in terms of medium-term
treatment efficacy was sustained in sensitivity analyses using an ITT
approach to missing data and a best-case scenario, but not in the
more conservative worst-case scenario.
Secondary outcomes
Evidence which was mostly of low certainty showed no differences
between behavioural activation and comparators in depression
symptoms, quality of life, functioning, and anxiety symptoms.
Most outcomes were measured between five and 12 months aNer
baseline measurements.
The two included studies did not report data on adverse effects.
Overall completeness and applicability of evidence
This review presents very limited evidence on behavioural
activation for depression in adults with NCDs.
Our focus on diagnosed depression in people with comorbid
CVD, diabetes, cancer, or respiratory illness means that studies of
participants with other NCDs or depression symptoms without a
formal diagnosis were not represented in this review. The evidence
from these studies does, therefore, not apply to people with mild
or subthreshold symptoms of depression. As commentary papers
of one of the included studies highlighted, the exclusion of people
with milder symptoms of depression will exclude a substantial
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proportion of people who show symptoms aNer being diagnosed
with an NCD or having experienced an event such as stroke (Barer
2010; Watkins 2009).
Although both studies reported several medium-term and long-
term outcomes, we could not draw conclusions on the longer-
term effectiveness of behavioural activation from the limited data
available. It is possible that the efficacy of behavioural activation
is affected by symptoms and the treatment process of the NCD at
the time of the intervention. For example, receiving treatment for
depression during or aNer treatment for cancer, or four months
rather than eight months aNer a stroke, may affect the efficacy of
behavioural activation.
Both studies were conducted in the US, with participants who were
predominantly White Americans and middle aged. This evidence
may, therefore, not apply to people in a different healthcare
setting, or to people with different individual characteristics and
determinants of health. In low- and middle-income countries,
variation in healthcare systems and the acceptability and
cultural appropriateness of mental health interventions such as
behavioural activation may affect the efficacy of the treatment.
Neither study reported on adverse effects resulting from receiving
the intervention or the comparator, although in one study it was
stated that there was monitoring of adverse effects throughout the
study (Mitchell 2008 under Mitchell 2009). As there were no data, we
cannot judge to what extent behavioural activation therapy in this
population may lead to adverse effects.
Quality of the evidence
Evidence was of low to moderate certainty. Evidence was
downgraded for risk of bias, mostly relating to risk of attrition bias,
performance bias, reporting bias, and potential conflict of interest,
and for lack of precision. There was insufficient evidence for any of
the outcomes to be certain that the reported estimates reflect the
true estimates for these outcomes. As it is not possible to assess
inconsistency in study results for outcomes with evidence based on
only one study, we were unable to downgrade for inconsistency for
these outcomes.
Potential biases in the review process
Our search strategy included regional and global databases and
grey literature to identify studies published worldwide. However,
the two studies eligible for inclusion were both conducted in the
US. It is possible that relevant literature from other countries was
missed, particularly if studies were not published in peer-reviewed
journals.
We applied strict selection criteria regarding study samples and
interventions. We only included studies with participants with
clinically diagnosed depression and one of four key NCDs. Other
evidence is available and may be informative to the treatment of
depressive symptoms in clinical practice, for example for people
with subthreshold depression, those who have not received a
formal diagnosis, or those with other chronic physical conditions.
Interventions for which behavioural activation was a component
but not the main part of the intervention were excluded, which
means interventions with relevance for clinical practice, such as
collaborative care without a substantial behavioural activation
component, were not included.
We used dropout from the studies as an indicator of treatment
acceptability. Although participants' dropout may be related to
satisfaction with the treatment, this is a crude indicator. Other
elements of treatment acceptability could be considered, such as
satisfaction measured through questionnaires.
Agreements and disagreements with other studies or
reviews
One recent Cochrane Review of behavioural activation in
depression for adults included evidence from 53 studies. It showed
that behavioural activation may be more effective than humanistic
therapy, medication, and treatment as usual, and that it may
be no less effective than CBT, psychodynamic therapy, or being
placed on a waiting list (Uphoff 2020). Treatment acceptability
was similar between behavioural activation and most comparison
groups. This indirect evidence suggests that behavioural activation
may be effective for the treatment of depression in people with
NCDs, although we do not currently know whether evidence can
be applied to this specific population, who may face different
challenges in overcoming depression.
One trial of 705 older adults comparing collaborative care with a
strong behavioural activation component to treatment as usual
found benefits of behavioural activation for the treatment of
subthreshold depression (Gilbody 2017). Among this study sample,
physical comorbidities including diabetes, cancer, respiratory
conditions, and heart disease were prevalent. However, this
trial did not meet the selection criteria for this review as the
population was selected based on age rather than presence
of NCDs. One systematic review and meta-analysis of 18 trials
of behavioural activation for the treatment of depression in
older people, including Gilbody 2017, showed that behavioural
activation reduced symptoms of depression more than treatment
as usual (Orgeta 2017).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Various global and national organisations advise on the treatment
of people with mental and physical health problems. The World
Health Organization advises that care for people with mental
disorders and physical comorbidities should be integrated and
collaborative, with professionals in primary care, hospital, and
mental health services all having a role to play (WHO 2017b).
The American Psychological Association (APA) guideline for the
treatment of depression recognises the importance of considering
comorbidities for the treatment of depression in adults and
older people. For older people with type 2 diabetes mellitus
or chronic obstructive pulmonary disease, a combination of
individual cognitive behavioural therapy (CBT) and usual care is
recommended (APA 2019). The Association of American Family
Physicians (AAFP) recommends antidepressant medication or CBT
(or both) to treat depression following an acute coronary syndrome
event (Frost 2019). The Cancer Care Ontario Program in Evidence-
Based Care guideline advises psychosocial or pharmacological (or
both) interventions for depression in people with cancer, with
collaborative care including an element of behavioural activation
therapy recommended for the treatment of major depression or
persistent subthreshold symptoms (Li 2016).
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Guidance from the UK on the treatment of depression in adults
with a chronic physical health problem was last updated in
2009 (NICE 2009). Behavioural activation is recommended for
the general population of adults with depression. For those with
chronic physical health problems in addition to depression, the
guideline recommends antidepressants and group-based CBT in
the first instance. Depending on suitability and depression severity,
individual CBT is also recommended.
The evidence from this review is not sufficient to draw conclusions
on the treatment of depression with behavioural activation for
people with NCDs in clinical practice. There was insufficient
evidence for adults with moderate-to-severe depression poststroke
or while receiving breast cancer treatment in the US. We found no
evidence for other settings or countries, people with other NCDs,
and formats of behavioural activation other than individual face-
to-face delivery by specialists or specialists in training. We did not
include any studies with participants with mild or subthreshold
depression.
Before implementing behavioural activation as an alternative to
other treatments for depression in this population, further research
is required to establish the efficacy and acceptability of behavioural
activation for the treatment of depression in adults with NCDs. It
has been suggested that behavioural activation is less complicated
than other psychological therapies to deliver and as such may
be suited to wider dissemination (Ekers 2014). There may be
the potential to implement behavioural activation in different
healthcare settings and clinics attended by people with NCDs.
Implications for research
Behavioural activation is increasingly being evaluated for the
treatment of depression or depressive symptoms in people with
NCDs. It is likely that a future review will be able to provide
more conclusive evidence on the efficacy and acceptability of
behavioural activation in this population.
This review did not include studies with participants with
symptoms of depression or subthreshold depression without a
formal diagnosis. Such studies could add to the evidence base,
as it is likely that many people with NCDs experience symptoms
of depression without meeting the criteria for a diagnosis, or
without receiving the formal clinical assessment required for a
diagnosis. Future reviews of behavioural activation for people with
NCDs may wish to include, or focus on, people with subthreshold
depression or symptoms of depression. This would inform whether
behavioural activation could be used to intervene early in this
population, applying a preventive public health perspective, before
depression develops or worsens.
Depression and NCDs such as diabetes, cancer, heart disease, and
chronic respiratory illness are common in high-income countries as
well as low- and middle-income countries. Given that behavioural
activation is seen as a treatment which might successfully be
delivered with fewer resources and less specialist training than
established psychological therapies, evidence from low- and
middle-income countries could establish whether behavioural
activation can be an effective, acceptable, and feasible alternative
in the treatment of depression among people with NCDs in settings
where resources for mental health support are limited.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: RCT
Study grouping: parallel group
Recruitment (how were participants recruited, where, when): 80 adults with a principal diagnosis
of major depression who were treated at the University of Tennessee Medical Center's Cancer Institute
(Knoxville, TN). Recruited through clinic screening, clinic brochures, and oncologist referral.
Hopko 2011 
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Type of RCT (blind, double-blind, open): open
Participants Baseline characteristics
BA
• Gender (n and % men and women): 100% women
• Ethnic group (n and % in each group): 90% Caucasian, 10% African American
• Occupation/employment (n and % in categories): employed (full time) = 7 (17%); employed (part-time)
= 9 (21%); unemployed = 11 (26%); retired = 15 (36%)
• Education level (n and % in categories): mean 15.1 years (SD 2.1)
• Comorbid anxiety (n and % of participants): generalised anxiety disorder = 21 (50%); social phobia = 4
(10%); post-traumatic stress disorder = 2 (5%); panic disorder = 2 (5%); specific phobia = 2 (5%); anxiety
disorder NOS = 1 (3%)
• Depression severity (mean score at baseline or n and % in categories): moderate, mean HRSD 19.2 (SD
7.0)
• Age: mean 56.4 (SD 11.1) years
• NCD: breast cancer
Problem-solving therapy
• Gender (n and % male and female): 100% women
• Ethnic group (n and % in each group): 95% Caucasian, 5% African American
• Occupation/employment (n and % in categories): employed (full time) = 10 (26%); employed (part-time)
= 8 (21%); unemployed = 11 (29%); retired = 9 (24%)
• Education level (n and % in categories): mean 14.5 years (SD 2.4)
• Comorbid anxiety (n and % of participants): generalised anxiety disorder = 14 (37%); social phobia = 5
(13%); post-traumatic stress disorder = 3 (8%); panic disorder = 0 (0%); specific phobia = 1 (3%); anxiety
disorder NOS = 0 (0%)
• Depression severity (mean score at baseline or n and % in categories): moderate, mean HRSD 20.1 (SD
5.9)
• Age: mean 54.3 (SD 11.2) years
• NCD: breast cancer
Included criteria: breast cancer, diagnosis of major depressive disorder (DSM-IV), aged ≥ 18 years,
moderate depressive symptoms
Excluded criteria: recent antidepressant or antianxiety medication not stabilised before starting trial,
bipolar disorder, psychosis, mental retardation, current alcohol or drug dependence, or principal diag-
nosis other than major depression.
Pretreatment: baseline characteristics largely similar. BA group less likely to have a history of psy-
chotherapy for depression, and more likely to have current antidepressant use and generalised anxiety
disorder. Pretreatment depression scores similar.
Interventions Intervention characteristics
BA
• Type of intervention (BA or comparator): BA
• Description of intervention: brief BA therapy for depression
• Dose (length of session): 1 hour per week
• Frequency: once a week
• Duration: 8 weeks
• Level of therapist (specialist or non-specialist): specialist in training
• Individual or group therapy: individual
• Mode of delivery (face-to-face, telephone, online, combination): face-to-face
• Modifications to intervention: participants were paid per session
Hopko 2011  (Continued)
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Problem-solving therapy
• Type of intervention (BA or comparator): comparator
• Description of intervention: problem-solving therapy
• Dose (length of session): 1 hour per week
• Frequency: once a week
• Duration: 8 weeks
• Level of therapist (specialist or non-specialist): specialist in training
• Individual or group therapy: individual
• Mode of delivery (face-to-face, telephone, online, combination): face-to-face
• Modifications to intervention: participants were paid per session
Outcomes Depression symptoms (HRSD)
• Outcome type: continuous
• Scale: HRSD
• Direction: lower is better
Remission (HRSD)
• Outcome type: dichotomous
• Scale: HRSD
• Direction: higher is better
• Data value: endpoint
Social functioning (physical component)
• Outcome type: continuous
• Scale: SF-36 physical
• Direction: higher is better
Quality of life
• Outcome type: continuous
• Scale: QOLI
• Direction: higher is better
• Data value: endpoint
Anxiety symptoms
• Outcome type: continuous
• Scale: BAI
• Direction: lower is better
• Data value: endpoint
Treatment acceptability (dropouts)
• Outcome type: dichotomous
• Reporting: fully reported
• Direction: lower is better
• Data value: endpoint
Identification Sponsorship source: research supported by Susan G. Komen for the Cure research grant awarded to
Derek R. Hopko (BCTR0706709)
Country: US
Setting: recruitment at medical centre cancer institute in Tennessee, US
Hopko 2011  (Continued)
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Comments: missing data imputed with multiple imputation.
Authors name: Derek R Hopko
Institution: University of Tennessee
Email: dhopko@utk.edu
Address: University of Tennessee, Knoxville, Department of Psychology, 307 Austin Peay Building,
Knoxville, TN 37996-0900, US.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "If included following the comprehensive assessment, based on a
preestablished randomization chart (Random Allocation Software, Version 1.0;
Saghaei, 2004), patients were randomized to either BATD [behavioural activa-
tion therapy for depression] or PST [problem-solving therapy]."










High risk Comment: blinding not possible due to nature of interventions. This may intro-
duce bias, e.g. if participants prefer 1 treatment over the other.
Blinding of outcome as-
sessment for the OBSERV-
ER-RATED scale (detection
bias)
Low risk Quote: "Advanced doctoral students in clinical psychology conducted the
comprehensive assessments. At the time of these assessments, examiners
were unaware of the potential treatment condition of the patient if included in
the study."




High risk Comment: missing outcome data: 10/42 in BA group and 5/38 in problem-solv-
ing therapy group was imputed using multiple imputation. Although miss-
ing data were reported to be missing at random, imputing outcome data may
have resulted in bias if attrition was related to satisfaction with the interven-
tion or with the allocation.
Selective reporting (re-
porting bias)
Unclear risk Comment: no reference to protocol or trial registration number.
Other bias High risk Comment: authors Derek R Hopko (principal investigator) and Carl W Lejuez
developed BA therapy for depression intervention and manuals, and would,
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Methods Study design: RCT
Study grouping: parallel group
Recruitment (how were participants recruited, where, when): people hospitalised in 4 acute care
hospitals in Seattle, US.
Type of RCT (blind, double-blind, open): open
Participants Baseline characteristics
BA + antidepressant
• Gender (n and % men and women): men 29 (60.4%) and women 19 (39.6%)
• Ethnic group (n and % in each group): Hispanic (intervention: 3 (6.3%); control: 2 (3.8%)); mixed race
(12 (25%)); white (29 (60.4%)); black (3 (6.3%)); Japanese (3 (6.3%)); Pacific islander (0%); Korean (1
(2.1%))
• Occupation/employment: -
• Education level: -
• Comorbid anxiety: -
• Depression severity (mean score at baseline or n and % in categories): mean HRSD 20.0 (SD 4.53); range
10–29
• Age: mean 57 (range 25–88) years
Treatment as usual + antidepressant
• Gender (n and % men and women): men 32 (60.4%) and women 21 (39.6%)
• Ethnic group (n and % in each group): Hispanic (2 (3.8%)); mixed race (10 (18.9%)); white (35, 66.0%);
black (7 (13.2%)); Japanese (0%); Pacific islander (1 (1.9%)); Korean (0%)
• Occupation/ employment: -
• Education level: -
• Comorbid anxiety: -
• Depression severity (mean score at baseline or N and % in categories): mean HRSD 19.8 (SD 4.15); range
11–29
• Age: mean 57 (range 29–88) years
Included criteria: within 4 months of an ischaemic stroke, screened positive for depressive symptoms,
diagnosis of clinical depression (DSM-IV).
Excluded criteria: prior or current treatment for depression
Pretreatment: similar baseline characteristics, stroke severity, and depression symptoms.
Interventions Intervention characteristics
BA + antidepressant
• Type of intervention (BA or comparator): BA
• Description of intervention: Living Well with Stroke
• Dose (length of session):
• Frequency: weekly (9 times in 8 weeks)
• Duration: 8 weeks
• Level of therapist (specialist or non-specialist): specialist
• Individual or group therapy: individual
• Mode of delivery (face-to-face, telephone, online, combination): face-to-face
• Modifications to intervention: -
Treatment as usual + antidepressant
Mitchell 2009  (Continued)
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• Type of intervention (BA or comparator): comparator
• Description of intervention: treatment as usual poststroke + antidepressant (sertraline first choice)
• Dose (length of session): -
• Frequency: -
• Duration: 8 weeks
• Level of therapist (specialist or non-specialist): -
• Individual or group therapy: individual
• Mode of delivery (face-to-face, telephone, online, combination): face-to-face
• Modifications to intervention: -
Outcomes Depression symptoms
• Outcome type: continuous
• Reporting: fully reported
• Scale: HRSD
• Direction: lower is better
• Data value: change from baseline
Remission (perceived recovery)
• Outcome type: dichotomous
• Scale: HRSD
• Direction: higher is better
• Data value: endpoint
• Notes: HRSD ≤ 9
Treatment acceptability (dropouts)
• Outcome type: dichotomous
• Reporting: fully reported
• Direction: lower is better
• Data value: endpoint
Identification Sponsorship source: National Institute of Nursing Research, National Institutes of Health grant R01N-
R007755
Country: US
Setting: 4 acute poststroke care hospitals in Seattle, Washington State, US
Comments: -
Authors name: Pamela H Mitchell
Institution: University of Washington
Email: pmitch@u.washington.edu
Address: Box 357266, University of Washington, Seattle, WA 98195-7266, US
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "masking – randomization status was generated by a computerized
adaptive randomization procedure after the method of Pocock and Simon."
Mitchell 2009  (Continued)
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Comment: computerised randomisation used.
Allocation concealment
(selection bias)
Low risk Comment: contacted author: allocation concealed from everyone except sta-





High risk Comment: no blinding of participants and personnel possible due to nature
of intervention. This may introduce bias, e.g. if some participants prefer psy-
chotherapy over medication only.
Blinding of outcome as-
sessment for the OBSERV-
ER-RATED scale (detection
bias)
Low risk Quote: "All outcome assessors were masked to the participant's randomiza-
tion status at each data collection point. We did not detect any breaches in
masking."




Low risk Comment: some reasons for dropout provided but not all. 4/48 in intervention
group and 5/53 in control group.
Selective reporting (re-
porting bias)
Low risk Quote: "http://www.clinicaltrials.gov/ct/show/NCT00194454?order=1"
Comment: trial registration reported; outcomes match registration.
Other bias High risk Comment: authors reported no conflicts of interest. Dr Teri, last author on this
publication, developed the intervention and, therefore, had an interest in it
being successful. She also supervised therapists. This may have caused bias.
Mitchell 2009  (Continued)
BA: behavioural activation; BAI: Beck Anxiety Inventory; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition;
HRSD: Hamilton Rating Scale for Depression; n: number; NCD: non-communicable disease; NOS: not otherwise specified; QOLI: Quality Of
Life Inventory; RCT: randomised controlled trial; SD: standard deviation; SF-36: 36-item Short Form.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Cully 2014 No formal clinical diagnosis of depression.
Humphreys 2015 No formal clinical diagnosis of depression.
ISRCTN11290592 No formal clinical diagnosis of depression.
ISRCTN12715175 No formal clinical diagnosis of depression.
ISRCTN16242820 No formal clinical diagnosis of depression.
ISRCTN16601130 No formal clinical diagnosis of depression.
ISRCTN63855912 No formal clinical diagnosis of depression.
Jahoda 2015 Not key NCD.
Kaltman 2016 No formal clinical diagnosis of depression.
Kirkness 2017 No formal clinical diagnosis of depression.
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Study Reason for exclusion
McGregor 2011 No formal clinical diagnosis of depression.
Mehnert 2014 No formal clinical diagnosis of depression.
Morgan 2009 No formal clinical diagnosis of depression.
Naik 2019 No formal clinical diagnosis of depression.
NCT01506492 No formal clinical diagnosis of depression.
NCT01572389 No formal clinical diagnosis of depression.
NCT02121340 No formal clinical diagnosis of depression.
NCT02353546 No formal clinical diagnosis of depression.
NCT02382562 Not key NCD.
NCT02413840 No formal clinical diagnosis of depression.
NCT02846662 Not key NCD.
NCT03026426 Not key NCD.
NCT03233451 No formal clinical diagnosis of depression.
NCT03431493 No formal clinical diagnosis of depression.
Richards 2018 No formal clinical diagnosis of depression.
Sareh 2016 No formal clinical diagnosis of depression.
Thomas 2019 No formal clinical diagnosis of depression.
Tindle 2012 No formal clinical diagnosis of depression.
NCD: non-communicable disease.
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Unclear
Participants 150 participants with depression and type 2 diabetes in India.
Interventions Physician-led counselling vs usual care
Outcomes Change in depression (SCL-90), glycaemic control
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Characteristics of ongoing studies [ordered by study ID]
 
Study name Personalized treatments for depressive symptoms in patients with advanced heart failure.
Methods RCT
Participants Adults with heart failure (II–IV) and depression
Interventions Behavioural activation and medication management
Outcomes Depression, generic health, cardiomyopathy, carer burden, emergency department visits, readmis-
sions, days in hospital, mortality
Starting date 9 November 2018
Contact information Vicki A Manoukian: vicki.manoukian@cshs.org
Notes Completion planned for 2021.
NCT03688100 
RCT: randomised controlled trial.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Behavioural activation (BA) versus any comparator





Statistical method Effect size
1.1 Treatment efficacy for depres-
sion (remission)
2   Risk Ratio (IV, Random, 95% CI) Subtotals only
1.1.1 Short-term (up to 6 months) 2 176 Risk Ratio (IV, Random, 95% CI) 1.53 [0.98, 2.38]
1.1.2 Medium-term (7–12
months)
1 92 Risk Ratio (IV, Random, 95% CI) 1.76 [1.01, 3.08]
1.1.3 Long-term (> 12 months) 1 67 Risk Ratio (IV, Random, 95% CI) 1.42 [0.91, 2.23]
1.2 Treatment acceptability
(dropouts)
2   Risk Ratio (IV, Random, 95% CI) Totals not selected
1.2.1 Short-term (up to 6 months) 1   Risk Ratio (IV, Random, 95% CI) Totals not selected
1.2.2 Medium-term (7–12
months)
1   Risk Ratio (IV, Random, 95% CI) Totals not selected
1.3 Improvement in depression
symptoms
2   Mean Difference (IV, Random, 95% CI) Subtotals only
1.3.1 Short-term (up to 6 months) 2 176 Mean Difference (IV, Random, 95% CI) -1.15 [-2.71, 0.41]
Behavioural activation therapy for depression in adults with non-communicable diseases (Review)
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Statistical method Effect size
1.3.2 Medium-term (7–12
months)
2 172 Mean Difference (IV, Random, 95% CI) -1.51 [-4.14, 1.12]
1.3.3 Long-term (> 12 months) 1 67 Mean Difference (IV, Random, 95% CI) -2.00 [-4.71, 0.71]
1.4 Quality of life 1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.4.1 Short-term (up to 6 months) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.4.2 Medium-term (7–12
months)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.5 Social adjustment and func-
tioning
1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.5.1 Short-term (up to 6 months) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.5.2 Medium-term (7–12
months)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.6 Improvement in anxiety
symptoms
1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.6.1 Short-term (up to 6 months) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.6.2 Medium-term (7–12
months)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.7 Treatment efficacy for depres-
sion – sensitivity analyses
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.7.1 Medium-term (up to 6
months) ITT
1 101 Risk Ratio (M-H, Random, 95% CI) 1.78 [1.01, 3.16]
1.7.2 Medium-term (up to 6
months) – best case
1 106 Risk Ratio (M-H, Random, 95% CI) 2.32 [1.34, 4.03]
1.7.3 Medium-term (up to 6
months) – worst case
1 101 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.79, 2.11]
 
 
Behavioural activation therapy for depression in adults with non-communicable diseases (Review)









Cochrane Database of Systematic Reviews
Analysis 1.1.   Comparison 1: Behavioural activation (BA) versus any
comparator, Outcome 1: Treatment efficacy for depression (remission)
Study or Subgroup





Heterogeneity: Tau² = 0.05; Chi² = 1.76, df = 1 (P = 0.19); I² = 43%
Test for overall effect: Z = 1.87 (P = 0.06)





Test for overall effect: Z = 1.99 (P = 0.05)





Test for overall effect: Z = 1.54 (P = 0.12)












































IV, Random, 95% CI
2.08 [1.13 , 3.82]
1.29 [0.92 , 1.82]
1.53 [0.98 , 2.38]
1.76 [1.01 , 3.08]
1.76 [1.01 , 3.08]
1.42 [0.91 , 2.23]
1.42 [0.91 , 2.23]
Risk Ratio
IV, Random, 95% CI
0.2 0.5 1 2 5
Favours comparator Favours BA
 
 
Analysis 1.2.   Comparison 1: Behavioural activation (BA) versus
any comparator, Outcome 2: Treatment acceptability (dropouts)
Study or Subgroup
1.2.1 Short-term (up to 6 months)
Hopko 2011

















IV, Random, 95% CI
1.81 [0.68 , 4.82]
0.88 [0.25 , 3.10]
Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours BA Favours comparator
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Analysis 1.3.   Comparison 1: Behavioural activation (BA) versus
any comparator, Outcome 3: Improvement in depression symptoms
Study or Subgroup




Heterogeneity: Tau² = 0.11; Chi² = 1.08, df = 1 (P = 0.30); I² = 7%
Test for overall effect: Z = 1.45 (P = 0.15)




Heterogeneity: Tau² = 2.44; Chi² = 3.03, df = 1 (P = 0.08); I² = 67%
Test for overall effect: Z = 1.12 (P = 0.26)



























































IV, Random, 95% CI
-0.60 [-2.38 , 1.18]
-2.30 [-4.97 , 0.37]
-1.15 [-2.71 , 0.41]
-0.30 [-2.07 , 1.47]
-3.00 [-5.47 , -0.53]
-1.51 [-4.14 , 1.12]
-2.00 [-4.71 , 0.71]
-2.00 [-4.71 , 0.71]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours BA Favours comparator
 
 
Analysis 1.4.   Comparison 1: Behavioural activation (BA) versus any comparator, Outcome 4: Quality of life
Study or Subgroup
1.4.1 Short-term (up to 6 months)
Hopko 2011























IV, Random, 95% CI
0.40 [-0.16 , 0.96]
-0.10 [-0.74 , 0.54]
Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours comparator Favours BA
 
 
Analysis 1.5.   Comparison 1: Behavioural activation (BA) versus
any comparator, Outcome 5: Social adjustment and functioning
Study or Subgroup
1.5.1 Short-term (up to 6 months)
Hopko 2011























IV, Random, 95% CI
2.70 [-6.99 , 12.39]
2.20 [-6.37 , 10.77]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours comparator Favours BA
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Analysis 1.6.   Comparison 1: Behavioural activation (BA) versus
any comparator, Outcome 6: Improvement in anxiety symptoms
Study or Subgroup
1.6.1 Short-term (up to 6 months)
Hopko 2011























IV, Random, 95% CI
-1.70 [-4.50 , 1.10]
-1.70 [-4.48 , 1.08]
Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours BA Favours comparator
 
 
Analysis 1.7.   Comparison 1: Behavioural activation (BA) versus any
comparator, Outcome 7: Treatment efficacy for depression – sensitivity analyses
Study or Subgroup





Test for overall effect: Z = 1.99 (P = 0.05)





Test for overall effect: Z = 3.00 (P = 0.003)





Test for overall effect: Z = 1.01 (P = 0.31)







































M-H, Random, 95% CI
1.78 [1.01 , 3.16]
1.78 [1.01 , 3.16]
2.32 [1.34 , 4.03]
2.32 [1.34 , 4.03]
1.29 [0.79 , 2.11]
1.29 [0.79 , 2.11]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours comparator Favours BA
 
 
A P P E N D I C E S
Appendix 1. Categories of psychological therapies
 
Categories Abbreviation Subcategories Abbreviation
Behavioural therapy (Lewinsohn) —1. Behavioural
therapies
BT
Behavioural activation (original model) (Jacobson) BA
 
Behavioural activation therapy for depression in adults with non-communicable diseases (Review)









Cochrane Database of Systematic Reviews
Social skills training/assertiveness training SST/assertion
Relaxation therapy —
Other behavioural therapies —
Cognitive therapy —
Rational emotive behaviour therapy —
Problem-solving therapy —
Self-control therapy —





Other cognitive behavioural therapies —
Acceptance and commitment therapy ACT
Compassionate mind training —
Functional analytic psychotherapy —
Extended behavioural activation eBA
Metacognitive therapy —
Mindfulness-based cognitive therapy —







Other third-wave cognitive and behavioural therapies
(other third-wave CBT)
—
Drive/structural model (Freud) —
Relational model (Strupp, Luborsky) —




Other psychodynamic therapies —
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Other humanistic therapies —
Interpersonal therapy IPT
Cognitive analytic therapy CAT
Psychodynamic interpersonal therapy —








Other integrative therapy approaches —
  (Continued)
 
Appendix 2. Full search strategy
CCMD Trials Register Search (current to 14 June 2016 only)
03/10/2019
#1 (depression or depressive disorder):mh,emt,kw,ky AND INREGISTER 20650
#2 (depress* adj3 (acute or clinical* or diagnos* or disorder* or major or unipolar or illness or scale* or score* or adult* or patient* or
participant* or people or inpatient* or in-patient* or outpatient* or out-patient*)):ab AND INREGISTER 15685
#3 (depress* and (Beck* or BDI* or DSM* or (Statistical Manual adj2 Mental Disorders) or Hamilton or HAM-D or HAMD or MADRS or
(International Classification adj2 Disease?) or ICD-10 or ICD-9)):ab AND INREGISTER 8670
#4 “with depressi*”:ab AND INREGISTER 2339
#5 (depressi* or depressed):ti AND INREGISTER 14828
#6 #1 OR #2 OR #3 OR #4 OR #5 24421
#7 ((behavio* adj1 activat*) or BATD) AND INREGISTER 197
#8 (behavio* and (self adj (evaluat* or monitor*))) AND INREGISTER 481
#9 (behavio* adj2 (contracting or modification or modify*)) AND INREGISTER 453
#10 reinforc* AND INREGISTER 311
#11 (activit* adj2 schedul*) AND INREGISTER 26
#12 ((pleas* or enjoy* or reward*) adj4 (activit* or event*)) AND INREGISTER 110
#13 ((operant or instrumental) adj (conditioning or learning)) AND INREGISTER 26
#14 (positive interaction* or avoida* coping or environmental contingenc* or contigency management) AND INREGISTER 50
#15 functional analysis AND INREGISTER 10
#16 ((gain or gains or reapprais*) adj2 focus*) AND INREGISTER 2
#17 ((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*)) AND INREGISTER 699
#18 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 (2142)
#19 #6 AND #18 (1051)
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#20 (behavio* adj (counsel* or intervention or train* or treatment or therapy or psychotherapy)) AND INREGISTER 9331
#21 #20 AND #6 (4402)
#22 ((long-term or longterm or chronic* or occupational) next (condition* or disease* or symptom* or problem* or failure*)) AND
INREGISTER 999
#23 (asthma* or bronchitis or chronic obstructive or emphysema or hypertension or lung or pulmonary or respiratory) AND INREGISTER
1053
#24 (obstruct* NEAR (airway* or airflow*)) AND INREGISTER 13
#25 ((hyper responsiveness or hyper-responsiveness or allergy or allergi* or hypersensitiv*) NEAR (airway*)) AND INREGISTER 0
#26 (COPD or COAD or COBD or AECB) AND INREGISTER 133
#27 diabet* or IDDM or NIDDM or MODY or T1DM or T2DM or T1D or T2D AND INREGISTER 521
#28 (cardio* or cardia* or CVD or heart* or coronary* or angina* or ventric* or myocard* or pericard* or ischem* or ischaem* cerebrovasc*
or stroke or strokes or poststroke or apoplexy or (brain NEAR (accident* or trauma*)) or ((brain* or cerebral or lacunar) NEAR infarct*)) AND
INREGISTER 3439
#29 hypertensi* or hyperlip* or hypercholester* or hypertriglycerid* or hyper-tensi* or hyper-lip* or hyper-cholester* or hyper-triglycerid*
or arteriosclerosis AND INREGISTER 386
#30 (emboli* or arrhythmi* or arteriosclero* or atherosclero* or peripheral arter* disease* or thrombo* or atrial fibrillat* or tachycardi* or
endocardi* or sick sinus) AND INREGISTER 391
#31 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leukemia* or leukaemia* or
metasta* or malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog* or psychooncology or psycho-oncology) AND
INREGISTER 1215
#32 #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 (6284)
#33 (#32 AND #19) 191
#34 (#21 AND #32) 676
#35 (#33 OR #34) 755
#36 (cholesterol* or “blood pressure”) AND INREGISTER 1223
#37 (#36 AND #19) 22
#38 (#36 AND #21) 63
#39 (#37 OR #38 OR #35) 779
#40 (CBT OR "cogniti* behavio*"):ti AND INREGISTER 2790
#41 (activat* or BATD or (self NEXT (evaluat* or monitor*)) or contracting or modification or modify* or (activit* and schedul*) or ((pleas* or
enjoy* or reward*) and (activit* or event*)) or ((operant or instrumental) and (conditioning or learning)) or positive interaction* or avoida*
coping or environmental contingenc* or contigency management or functional analysis or ((gain or gains or reapprais*) and focus*) or
((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*))):ti AND INREGISTER 447
#42 (#40 NOT #41) 2732




Condition or disease: Depression
Other terms: diabetes OR cancer or neoplasm OR tumor OR tumour OR asthma OR stroke or hypertension
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Study Type: Interventional Studies
Study results: All studies
Age group – Adult plus Older adult
Intervention: behaviour activation OR behavior activation OR behavioural activation OR behavioral activation
21 hits
Search 2
Condition or disease: Depression
Other terms: CVD OR cardiovascular OR cardiac OR heart OR coronary OR angina OR ventricular OR myocardial
Study Type: Interventional Studies
Study results: All studies
Age group – Adult plus Older adult
Intervention: behaviour activation OR behavior activation OR behavioural activation OR behavioral activation
25 hits
Search 3
Condition or disease: Depression
Other terms: ischemia OR ischaemia OR cerebrovascular OR COPD OR pulmonary OR lung OR respiratory OR bronchitis
Study Type: Interventional Studies
Study results: All studies
Age group – Adult plus Older adult
Intervention: behaviour activation OR behavior activation OR behavioural activation OR behavioral activation
10 studies
Search 4
Condition or disease: Depression
Other terms: diabetes OR cancer or neoplasm OR tumor OR tumour OR asthma OR stroke or hypertension
Study Type: Interventional Studies
Study results: All studies
Age group – Adult plus Older adult
Intervention: behaviour therapy OR behavior therapy OR behavioural therapy OR behavioral therapy
109 hits
Search 5
Condition or disease: Depression
Other terms: CVD OR cardiovascular OR cardiac OR heart OR coronary OR angina OR ventricular OR myocardial
Study Type: Interventional Studies
Study results: All studies
Age group – Adult plus Older adult
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Intervention: behaviour therapy OR behavior therapy OR behavioural therapy OR behavioral therapy
113
Search 6
Condition or disease: Depression
Other terms: ischemia OR ischaemia OR cerebrovascular OR COPD OR pulmonary OR lung OR respiratory OR bronchitis
Study Type: Interventional Studies
Study results: All studies
Age group – Adult plus Older adult
Intervention: behaviour therapy OR behavior therapy OR behavioural therapy OR behavioral therapy
51 hits
Cochrane Central Register of Controlled Trials Issue 9 of 12, September 2019
03/10/2019
ID Search Hits
#1 (((behavio* Near/1 activat*) or BATD)):ti,ab,kw 737
#2 behavio* and (self NEXT (evaluat* or monitor*)):ti,ab,kw 1978
#3 (behavio* near/2 (contracting or modification or modify*)):ti,ab,kw 1490
#4 reinforc*:ti,kw 2608
#5 (reinforce or reinforcer or reinforcement or reinforcements or re-inforcement or re-inforcements):ab 3988
#6 (reinforc* near/3 (behavio* or environment* or experience*)):ti,ab,kw 356
#7 (reinforc* near/1 (positive or contingent)):ti,ab,kw 319
#8 (activit* near/2 schedul*):ti,ab,kw 190
#9 ((pleas* or enjoy* or reward*) near/4 (activit* or event*)):ti,ab,kw 702
#10 ((operant or instrumental) NEXT (conditioning or learning)):ti,ab,kw 193
#11 ("positive interaction" or "positive interactions" or "avoidance coping" or "environmental contingency" or "environmental
contingencies" or "contingency management"):ti,ab,kw 938
#12 "functional analysis":ti,ab,kw 204
#13 ((gain* or reapprais*) near/2 focus*):ti,ab,kw 44
#14 ((psychoeducat* or psycho-educat*) and (behavi* or coping or (self and manage))):ti,ab,kw 2168
#15 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 13058
#16 MeSH descriptor: [Depression] this term only 10565
#17 MeSH descriptor: [Depressive Disorder] this term only 6862
#18 MeSH descriptor: [Depressive Disorder, Major] this term only 4338
#19 (depressi* or depressed):ti 27584
#20 (depress* near/3 (acute or clinical* or diagnos* or disorder* or major or unipolar or illness or scale* or score* or adult* or patient* or
participant* or people or inpatient* or outpatient*)):ab 32686
#21 (depress* near/3 ("in-patient*" or "out-patient*")):ab 54
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#22 (depress* and (Beck* or BDI* or DSM* or (Statistical Manual near/2 Mental Disorders) or Hamilton or HAM-D or HAMD or MADRS or
(International Classification near/2 Disease*) or ICD-10 or ICD-9)):ab 15159
#23 ("with depression" or "with depressive"):ab 3716
#24 #16 or #17 or #18 or #19 or #20 or #21 or #21 or #22 or #23 50806
#25 #15 and #24 1795
#26 MeSH descriptor: [Behavior Therapy] this term only 4354
#27 (behavio* next (counsel* or intervention or train* or treatment or therapy or psychotherapy)):ti,ab,kw 25050
#28 #26 or #27 25050
#29 #24 and #28 5948
#30 #25 or #29 6963
#31 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] this term only 4575
#32 MeSH descriptor: [Bronchitis, Chronic] this term only 148
#33 MeSH descriptor: [Pulmonary Emphysema] this term only 266
#34 MeSH descriptor: [Lung Diseases, Obstructive] this term only 2532
#35 MeSH descriptor: [Asthma] explode all trees 11043
#36 MeSH descriptor: [Respiratory Hypersensitivity] explode all trees 13717
#37 MeSH descriptor: [Hypertension, Pulmonary] this term only 867
#38 asthma*:ti,ab,kw 32702
#39 ((long-term or longterm or chronic*) near/5 (bronchitis or respirat*)):ti,ab,kw 4205
#40 emphysema*:ti,ab,kw 1435
#41 (obstruct* near/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)):ti,ab,kw 18195
#42 (("hyper responsiveness" or hyper-responsiveness or allergy or allergi* or hypersensitiv*) near/5 (airway* or respirat*)):ti,ab,kw 1385
#43 ((long-term or longterm or "long term" or Chronic* or occupational) near/2 lung* near/5 (condition* or disease* or symptom* or
problem* or failure*)):ti,ab,kw 7277
#44 (respirat* near/2 (condition* or disease* or symptom* or problem*)):ti,ab,kw 8212
#45 ("pulmonary hypertension"):ti,ab,kw 2830
#46 (COPD or COAD or COBD or AECB):ti,ab,kw 15065
#47 #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 66364
#48 MeSH descriptor: [Diabetes Mellitus] explode all trees 27785
#49 MeSH descriptor: [Glucose Tolerance Test] this term only 1966
#50 MeSH descriptor: [Glycated Hemoglobin A] this term only 5423
#51 diabet*:ti,ab,kw 85787
#52 (noninsulin* or "non*insulin*" or "non*insulin*" AND depend*):ti,ab,kw 15762
#53 ("fasting glucose" or "plasma glucose" or "glucose tolerance test" or "glucose tolerance tests" or "glucose tolerance testing" or
(glyc*emic near/2 control*)):ti,ab,kw 25536
#54 (HbA1c or A1C or A1c or Hb1c or ((glycated or glycosylated) near h*emoglobin*)):ti,ab,kw 24356
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#55 (NIDDM or T2D or T2DM):ti,ab,kw 8929
#56 #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 93958
#57 MeSH descriptor: [Diabetes Insipidus] explode all trees 62
#58 "diabetes insipidus":ti,ab,kw 141
#59 #57 or #58 142
#60 #54 not #58 24356
#61 MeSH descriptor: [Cardiovascular Diseases] explode all trees 98577
#62 (cardio* or cardia* or CVD):ti,ab,kw 137734
#63 (heart* or coronary*):ti,ab,kw 163233
#64 (angina* or ventric*):ti,ab,kw 42095
#65 (myocard* or pericard*):ti,ab,kw 43303
#66 (isch*em* or cerebrovasc*):ti,ab,kw 56095
#67 MeSH descriptor: [Stroke] explode all trees 8541
#68 (stroke or strokes or poststroke):ti,ab,kw 52250
#69 apoplexy:ti,ab,kw 325
#70 (brain near/2 accident*):ti,ab,kw 215
#71 ((brain* or cerebral or lacunar) near/2 infarct*):ti,ab,kw 4674
#72 MeSH descriptor: [Hypertension] explode all trees 16863
#73 (hypertensi* or hyperlip*):ti,ab,kw 67411
#74 (hypercholester* or hypertriglycerid*):ti,ab,kw 9436
#75 MeSH descriptor: [Arteriosclerosis] explode all trees 9205
#76 (arteriosclero* or atherosclero* or "peripheral arter* disease*"):ti,ab,kw 12614
#77 MeSH descriptor: [Cholesterol] explode all trees 9952
#78 cholesterol:ti,ab,kw 34711
#79 MeSH descriptor: [Blood Pressure] this term only 26032
#80 "blood pressure":ti,ab,kw 84592
#81 (emboli* or arrhythmi*):ti,ab,kw 21574
#82 (thrombo* or "atrial fibrillation"):ti,ab,kw 58813
#83 (tachycardi* or endocardi* or "sick sinus"):ti,ab,kw 9537
#84 #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80
or #81 or #82 or #83 386929
#85 MeSH descriptor: [Neoplasms] explode all trees 71857
#86 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk*emia* or metasta* or malignan*
or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog* or psychooncology or psycho-oncology):ti,ab,kw 222547
#87 #85 or #86 225813
#88 #47 or #60 or #84 or #87 640341
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#89 #30 and #88 1007
990 trials in CENTRAL
DART-Europe E-theses Portal (www.dart-europe.eu/)
25/09/2019
*really hard to search- the ‘refine’ option doesn’t work. I can only do a search in 1 line that works properly.
"behavioural activation" OR "behavioral activation" OR "behavior activation" OR "behaviour activation"
29 hits
(behaviour OR behavior) AND therapy AND Depression AND (Trial* OR random* OR RCT OR placebo* OR review*)
56 hits
Embase Classic+Embase 1947 to 2019 September 24
25/09/2019
1 ((behavio* adj1 activat*) or BATD).tw,kw. (2705)
2 behavio*.mp. and (self adj (evaluat* or monitor*)).tw,kw. (4865)
3 (behavio* adj2 (contracting or modification or modify*)).tw,kw. (8869)
4 reinforc*.ti,kw. (21802)
5 (reinforce or reinforcer or reinforcement or reinforcements or re-inforcement or re-inforcements).ab. /freq=2 (12814)
6 (reinforc* adj3 (behavio* or environment* or experience*)).tw,kw. (4620)
7 (reinforc* adj1 (positive or contingent)).tw,kw. (3282)
8 (activit* adj2 schedul*).tw,kw. (775)
9 ((pleas* or enjoy* or reward*) adj4 (activit* or event?)).tw,kw. (4952)
10 ((operant or instrumental) adj (conditioning or learning)).tw,kw. (4383)
11 (positive interaction* or avoida* coping or environmental contingenc* or contingency management).tw,kw. (5673)
12 functional analysis.tw,kw. (28567)
13 ((gain? or reapprais*) adj2 focus*).tw,kw. (182)
14 ((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*)).ti,ab,kw. (4345)
15 or/1-14 [Behavioural Activation] (95541)
16 exp depression/ (462857)
17 (depressi* or depressed).tw,kw. (604971)
18 dysthymi*.tw,kw. (4289)
19 distress*.ti,kw. (44962)
20 (mood? or mental health).tw,kw. (277403)
21 ((emotion* or psychological) adj (trauma* or distress*)).tw,kw. (34773)
22 "common mental disorder*".tw,kw. (2757)
23 or/16-22 [Depression - Cochrane terms] (980385)
24 15 and 23 [BA and Depression] (8762)
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25 behavior therapy/ (43569)
26 (behavio* adj (counsel* or intervention or train* or treatment or therapy or psychotherapy)).tw,kw. (44197)
27 25 or 26 (73524)
28 23 and 27 [Behaviour Therapy and Depression] (21614)
29 24 or 28 [BA or Behaviour Therapy AND Depression] (28601)
30 chronic obstructive lung disease/ (126011)
31 chronic bronchitis/ (14926)
32 exp lung emphysema/ (26142)
33 exp asthma/ (266419)
34 exp respiratory tract allergy/ (305469)
35 pulmonary hypertension/ (82989)
36 asthma*.tw,kw. (234792)
37 ((long-term or longterm or chronic*) adj5 (bronchitis or respirat*)).tw,kw. (41118)
38 emphysema*.tw,kw. (42290)
39 (obstruct* adj3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)).tw,kw. (127460)
40 ((hyper responsiveness or hyper-responsiveness or allergy or allergi* or hypersensitiv*) adj5 (airway? or respirat*)).tw,kw. (19564)
41 ((long-term or longterm or Chronic* or occupational) adj2 lung* adj5 (condition* or disease* or symptom* or problem* or failure*)).tw,kw.
(22365)
42 (respirat* adj2 (condition* or disease* or symptom* or problem*)).tw,kw. (83660)
43 pulmonary hypertension.tw,kw. (60555)
44 (COPD or COAD or COBD or AECB).tw,kw. (83692)
45 or/30-44 [Chronic Respiratory Diseases] (700497)
46 exp diabetes mellitus/ (960552)
47 exp glucose tolerance test/ (64609)
48 exp glycosylated hemoglobin/ (118751)
49 diabet*.tw,kw. (941196)
50 (noninsulin*-depend* or non-insulin*-depend* or noninsulin*depend* or non-insulin*depend*).tw,kw. (14890)
51 (fasting glucose or plasma glucose or glucose tolerance test* or (glyc?emic adj2 control*)).tw,kw. (145120)
52 (HbA1c or A1C or A1c or Hb1c or ((glycated or glycosylated) adj h?emoglobin?)).tw,kw. (98665)
53 (NIDDM or T2D or T2DM).tw,kw. (85587)
54 or/46-53 (1196262)
55 exp diabetes insipidus/ (16453)
56 diabet* insipidus.tw,kw. (12361)
57 55 or 56 (18000)
58 54 not 57 [Diabetes] (1182119)
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59 exp cardiovascular disease/ (4289589)
60 (cardio* or cardia* OR cvd).tw,kw. (1761464)
61 (heart* or coronary*).tw,kw. (1618428)
62 (angina* or ventric*).tw,kw. (680155)
63 (myocard* or pericard*).tw,kw. (614219)
64 (isch?em* or cerebrovasc*).tw,kw. (623781)
65 exp cerebrovascular accident/ (201090)
66 (stroke or strokes or poststroke).tw,kw. (387374)
67 apoplexy.tw,kw. (4279)
68 (brain adj2 accident*).tw,kw. (257)
69 ((brain* or cerebral or lacunar) adj2 infarct*).tw,kw. (40499)
70 elevated blood pressure/ or exp hypertension/ or exp blood pressure/ (1170153)
71 blood pressure.tw,kw. (438440)
72 (hypertensi* or hyperlip*).tw,kw. (719324)
73 (hypercholester* or hypertriglycerid*).tw,kw. (68908)
74 exp arteriosclerosis/ (267676)
75 exp cholesterol/ (325632)
76 (cholesterol or arteriosclero* or atherosclero* or peripheral arter* disease*).tw,kw. (330448)
77 (emboli* or arrhythmi*).tw,kw. (333497)
78 (thrombo* or "atrial fibrillat*").tw,kw. (657257)
79 (tachycardi* or endocardi* or "sick sinus").tw,kw. (166058)
80 or/59-79 [CVD] (6028103)
81 exp neoplasm/ (4693885)
82 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or malignan*
or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog* or psychoongology or psycho-oncology).tw,kw. (5006829)
83 81 or 82 [Cancer] (5875965)
84 45 or 58 or 80 or 83 [COPD Diabetes CVD or Cancer] (12099598)
85 exp randomized controlled trial/ (576165)
86 exp double-blind procedure/ (169084)
87 exp single-blind procedure/ (36791)
88 exp crossover-procedure/ (61344)
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93 trial.ti. (290797)
94 clinical trial*.tw. (497341)
95 (randomly or randomis* or randomiz*).tw,kw. (1206723)
96 controlled clinical trial/ (465844)
97 or/85-96 [RCT or CCT] (2106740)
98 exp animals/ not exp humans/ (5315473)
99 exp nonhuman/ not exp human/ (4490184)
100 exp experimental animal/ (673589)
101 exp veterinary medicine/ (45399)
102 animal experiment/ (2442893)
103 or/98-102 [Animal studies] (7516518)
104 97 not 103 [Final RCT search] (1874512)
105 29 and 84 and 104 [BA or Behaviour therapy and CMDs and COPD Diabetes CVD and RCTs] (1984)
106 29 and 84 (4855)
107 limit 106 to (meta analysis or "systematic review") (363)
108 ((systematic adj2 review*) or scoping review* or synthesis or meta-analys* or "meta analysis").ti. (623967)
109 106 and 108 (157)
110 ("Search filter*" or "search strateg*" or "literature search*").ab. (75378)
111 106 and 110 (57)
112 107 or 109 or 111 (417)
113 105 or 112 [BA or Behaviour Therapy and CMDs and COPD Diabetes CVD and RCTs OR systematic reviews] (2165)
114 exp juvenile/ not exp adult/ (2455191)
115 113 not 114 (2045)
EThOS - the British Libraries e-theses online service (ethos.bl.uk/) – Advanced search]
25/09/2019
6 separate searches to run then combine results, remove duplicates…
Search 1
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6 hits
Global Health 1910 to 2019 Week 36
25/09/2019
1 ((behavio* adj1 activat*) or BATD).tw,id. (106)
2 behavio*.mp. and (self adj (evaluat* or monitor*)).tw,id. (668)
3 (behavio* adj2 (contracting or modification or modify*)).tw,id. (2946)
4 reinforc*.ti,id. (733)
5 (reinforce or reinforcer or reinforcement or reinforcements or re-inforcement or re-inforcements).ab. /freq=2 (554)
6 (reinforc* adj3 (behavio* or environment* or experience*)).tw,id. (349)
7 (reinforc* adj1 (positive or contingent)).tw,id. (195)
8 (activit* adj2 schedul*).tw,id. (75)
9 ((pleas* or enjoy* or reward*) adj4 (activit* or event?)).tw,id. (441)
10 ((operant or instrumental) adj (conditioning or learning)).tw,id. (119)
11 (positive interaction* or avoida* coping or environmental contingenc* or contingency management).tw,id. (618)
12 functional analysis.tw,id. (1585)
13 ((gain? or reapprais*) adj2 focus*).tw,id. (28)
14 ((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*)).ti,ab,id. (185)
15 or/1-14 [Behavioural Activation] (8115)
16 depression/ (20888)
17 (depressi* or depressed).tw,id. (49196)
18 dysthymi*.tw,id. (202)
19 distress*.tw,id. (13076)
20 (mood? or mental health or ((emotion* or psychological) adj trauma*)).tw,id. (32705)
21 "common mental disorder*".tw,id. (660)
22 or/16-21 [Depression] (82061)
23 15 and 22 [BA and Depression] (560)
24 psychotherapy/ (1351)
25 (behavio* adj (counsel* or intervention or train* or treatment or therapy or psychotherapy)).tw,id. (4535)
26 24 or 25 [Behaviour therapy] (5449)
27 22 and 26 [Behaviour Therapy and Depression] (1085)
28 23 or 27 [BA or Behaviour Therapy AND Depression] (1557)
29 respiratory diseases/ or allergic bronchopulmonary aspergillosis/ or asthma/ or bronchitis/ or chronic obstructive pulmonary disease/
or pulmonary emphysema/ (85849)
30 asthma*.tw,id. (29430)
31 ((long-term or longterm or chronic*) adj5 (bronchitis or respirat*)).tw,id. (5484)
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32 emphysema*.tw,id. (2674)
33 (obstruct* adj3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)).tw,id. (10440)
34 ((hyper responsiveness or hyper-responsiveness or allergy or allergi* or hypersensitiv*) adj5 (airway? or respiratory)).tw,id. (5594)
35 ((long-term or longterm or Chronic* or occupational) adj2 lung* adj5 (condition* or disease* or symptom* or problem* or failure*)).tw,id.
(1991)
36 (respiratory adj2 (condition* or disease* or symptom* or problem*)).tw,id. (72584)
37 pulmonary hypertension.tw,id. (1285)
38 (COPD or COAD or COBD or AECB).tw,id. (5071)
39 or/29-38 [Chronic Respiratory Diseases] (102992)
40 diabetes/ or diabetes mellitus/ or glucose tolerance test/ (84582)
41 diabetes/ or diabetes mellitus/ (83522)
42 glucose tolerance test/ (1958)
43 blood sugar/ (47205)
44 diabet*.tw,id. (130275)
45 (noninsulin*-depend* or non-insulin*-depend* or noninsulin*depend* or non-insulin*depend*).tw,id. (2029)
46 (fasting glucose or plasma glucose or glucose tolerance test* or (glyc?emic adj2 control*)).tw,id. (26556)
47 (HbA1c or A1C or A1c or Hb1c or ((glycated or glycosylated) adj h?emoglobin?)).tw,id. (10369)
48 (NIDDM or T2D or T2DM).tw,id. (9180)
49 or/40-48 [Diabetes] (156940)
50 exp cardiovascular diseases/ (121130)
51 (cardio* or cardia* or cvd).tw,id. (133892)
52 (heart* or coronary*).tw,id. (117744)
53 (angina* or ventric*).tw,id. (17400)
54 (myocard* or pericard*).tw,id. (31877)
55 (isch?em* or cerebrovasc*).tw,id. (26569)
56 exp stroke/ (11434)
57 (stroke or strokes or poststroke).tw,id. (18935)
58 apoplexy.tw,id. (166)
59 (brain adj2 accident*).tw,id. (5)
60 ((brain* or cerebral or lacunar) adj2 infarct*).tw,id. (2156)
61 exp hypertension/ (40299)
62 (hypertensi* or hyperlip*).tw,id. (67458)
63 (hypercholester* or hypertriglycerid*).tw,id. (15474)
64 exp atherosclerosis/ (18021)
65 cholesterol/ (62723)
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66 (cholesterol or arteriosclero* or atherosclero* or peripheral arter* disease*).tw,id. (90502)
67 blood pressure/ (36160)
68 blood pressure.tw,id. (69564)
69 (emboli* or arrhythmi*).tw,id. (8651)
70 (thrombo* or "atrial fibrillat*").tw,id. (30155)
71 (tachycardi* or endocardi* or "sick sinus").tw,id. (10719)
72 or/50-71 [CVD] (360573)
73 exp neoplasms/ (225495)
74 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or malignan*
or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog* or psychoongology or psycho-oncology).tw,id. (435173)
75 73 or 74 [Cancer] (437583)
76 39 or 49 or 72 or 75 [COPD Diabetes CVD or Cancer] (916371)
77 clinical trials/ or randomized controlled trials/ (54715)
78 placebos/ (2370)
79 trial.ti. (32112)
80 ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw. (26857)
81 placebo*.tw. (35290)
82 (random* not (random sampl* or random digit* or random effect* or random survey or random regression)).tw. (183238)
83 or/77-82 [RCT] (215375)
84 28 and 76 and 83 [BA or Behaviour therapy and CMDs and COPD Diabetes CVD and RCTs] (93)
85 ((systematic adj2 review*) or scoping review* or synthesis or meta-analys* or "meta analysis").ti. (54215)
86 ("Search filter*" or "search strateg*" or "literature search*").ab. (8107)
87 85 or 86 (58255)
88 28 and 76 and 87 [Systematic Reviews] (8)
89 84 or 88 [BA or Behaviour Therapy and CMDs and COPD Diabetes CVD and RCTs OR systematic reviews] (98)
Global Index Medicus
25/09/2019
(behavio* AND (activat* OR activity OR "self evaluation" OR "self monitor*" OR modification OR modify* OR contracting OR reinforc* OR
psycho-education OR psychoeduction)) OR ("behavio* therapy") [in Title, abstract, subject]
AND
trial or trials or placebo* or rct or random* or review* or overview or meta-analysis [in Title, abstract, subject]
AND
diabet* OR cancer* or neoplas* OR tumor* OR tumour* OR asthma* OR stroke or hypertensi* OR CVD or cardio* OR cardia* OR heart* OR
coronary* OR angina* OR ventric* OR myocard* OR ischemi* OR r ischaemi* OR cerebrovasc OR COPD OR pulmonary OR lung* OR bronch*
OR respirat* [in Title, abstract, subject]
AND
depress* or "low mood*" or dysthymi* [in Title, abstract, subject]
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115 hits
WPRIM (Western Pacific) (63)
LILACS (Americas) (35)
IMEMR (Eastern Mediterranean) (15)
IMSEAR (South-EastAsia) (2)
IRIS (WHO) – Use Advanced Filters mode.
25/09/2019
apps.who.int/iris/discover?query=trial+or+trials+or+rct+or+random+or+randomised+or+randomized+or+randomly




Subject: Behavior or behaviour or behavioral or behavioural
0 hits
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 1946 to September 23, 2019
25/09/2019
1 ((behavio* adj1 activat*) or BATD).tw,kf. (2217)
2 behavio*.mp. and (self adj (evaluat* or monitor*)).tw,kf. (3556)
3 (behavio* adj2 (contracting or modification or modify*)).tw,kf. (6565)
4 reinforc*.ti,kf. (19262)
5 (reinforce or reinforcer or reinforcement or reinforcements or re-inforcement or re-inforcements).ab. /freq=2 (11015)
6 (reinforc* adj3 (behavio* or environment* or experience*)).tw,kf. (3798)
7 (reinforc* adj1 (positive or contingent)).tw,kf. (2505)
8 (activit* adj2 schedul*).tw,kf. (530)
9 ((pleas* or enjoy* or reward*) adj4 (activit* or event?)).tw,kf. (3574)
10 ((operant or instrumental) adj (conditioning or learning)).tw,kf. (3244)
11 (positive interaction* or avoida* coping or environmental contingenc* or contingency management).tw,kf. (4534)
12 functional analysis.tw,kf. (22895)
13 ((gain? or reapprais*) adj2 focus*).tw,kf. (158)
14 ((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*)).ti,ab,kf. (2601)
15 or/1-14 [Behavioural Activation] (76489)
16 Depression/ (111569)
17 exp depressive disorder/ (105157)
18 (depressi* or depressed).tw,kf. (421697)
19 dysthymi*.tw,kf. (3109)
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20 distress*.tw,kf. (116243)
21 (mood? or mental health or ((emotion* or psychological) adj trauma*)).tw,kf. (207320)
22 "common mental disorder*".tw,kf. (2311)
23 or/16-22 [Depression - Cochrane terms] (694602)
24 15 and 23 [BA and Depression] (5868)
25 Behavior Therapy/ (27103)
26 (behavio* adj (counsel* or intervention or train* or treatment or therapy or psychotherapy)).tw,kf. (29894)
27 25 or 26 [Behaviour therapy] (51473)
28 23 and 27 [Behaviour Therapy and Depression] (12629)
29 24 or 28 [BA or Behaviour Therapy AND Depression] (17366)
30 Pulmonary disease, chronic obstructive/ (36943)
31 Bronchitis, chronic/ or Pulmonary emphysema/ (17095)
32 Lung diseases, obstructive/ (18142)
33 exp Asthma/ (124320)
34 exp Respiratory Hypersensitivity/ (150812)
35 Hypertension, Pulmonary/ (33256)
36 asthma*.tw,kf. (153407)
37 ((long-term or longterm or chronic*) adj5 (bronchitis or respirat*)).tw,kf. (25995)
38 emphysema*.tw,kf. (26832)
39 (obstruct* adj3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)).tw,kf. (83455)
40 ((hyper responsiveness or hyper-responsiveness or allergy or allergi* or hypersensitiv*) adj5 (airway? or respirat*)).tw,kf. (12659)
41 ((long-term or longterm or Chronic* or occupational) adj2 lung* adj5 (condition* or disease* or symptom* or problem* or failure*)).tw,kf.
(14417)
42 (respirat* adj2 (condition* or disease* or symptom* or problem*)).tw,kf. (56825)
43 pulmonary hypertension.tw,kf. (34943)
44 (COPD or COAD or COBD or AECB).tw,kf. (43789)
45 or/30-44 [Chronic Respiratory Diseases] (409808)
46 exp Diabetes mellitus/ (407656)
47 Glucose Tolerance Test/ (33774)
48 Glycated Hemoglobin A/ (33142)
49 diabet*.tw,kf. (601034)
50 (noninsulin*-depend* or non-insulin*-depend* or noninsulin*depend* or non-insulin*depend*).tw,kf. (12152)
51 (fasting glucose or plasma glucose or glucose tolerance test* or (glyc?emic adj2 control*)).tw,kf. (92016)
52 (HbA1c or A1C or A1c or Hb1c or ((glycated or glycosylated) adj h?emoglobin?)).tw,kf. (50626)
53 (NIDDM or T2D or T2DM).tw,kf. (48996)
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54 or/46-53 (698768)
55 exp Diabetes Insipidus/ (7771)
56 diabet* insipidus.tw,kf. (8651)
57 55 or 56 (10648)
58 54 not 57 [Diabetes] (689642)
59 exp Cardiovascular Diseases/ (2304392)
60 (cardio* or cardia* or cvd).tw,kf. (1148831)
61 (heart* or coronary*).tw,kf. (1096235)
62 (angina* or ventric*).tw,kf. (443815)
63 (myocard* or pericard*).tw,kf. (412274)
64 (isch?em* or cerebrovasc*).tw,kf. (407127)
65 exp Stroke/ (125438)
66 (stroke or strokes or poststroke).tw,kf. (235050)
67 apoplexy.tw,kf. (3021)
68 (brain adj2 accident*).tw,kf. (161)
69 ((brain* or cerebral or lacunar) adj2 infarct*).tw,kf. (25996)
70 exp Hypertension/ (247564)
71 (hypertensi* or hyperlip*).tw,kf. (449183)
72 (hypercholester* or hypertriglycerid*).tw,kf. (46305)
73 exp Arteriosclerosis/ (170257)
74 exp Cholesterol/ (156627)
75 (cholesterol or arteriosclero* or atherosclero* or peripheral arter* disease*).tw,kf. (235241)
76 Blood Pressure/ (269165)
77 blood pressure.tw,kf. (293222)
78 (emboli* or arrhythmi*).tw,kf. (212813)
79 (thrombo* or "atrial fibrillat*").tw,kf. (414307)
80 (tachycardi* or endocardi* or "sick sinus").tw,kf. (108374)
81 or/59-80 [CVD] (3931951)
82 exp Neoplasms/ (3218192)
83 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or malignan*
or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog* or psychoongology or psycho-oncology).tw,kf. (3581527)
84 82 or 83 [Cancer] (4249796)
85 45 or 58 or 81 or 84 [COPD Diabetes CVD or Cancer] (8430805)
86 randomized controlled trial.pt. (489727)
87 controlled clinical trial.pt. (93263)
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88 randomized.ab. (454879)
89 placebo.ab. (200744)
90 clinical trials as topic.sh. (188454)
91 randomly.ab. (318349)
92 trial.ti. (204932)
93 86 or 87 or 88 or 89 or 90 or 91 or 92 (1239133)
94 exp animals/ not humans.sh. (4617436)
95 93 not 94 (1139614)
96 29 and 85 and 95 [BA or Behaviour therapy and CMDs and COPD Diabetes CVD and RCTs] (867)
97 29 and 85 (2140)
98 limit 97 to "systematic review" (82)
99 96 or 98 [BA or Behaviour Therapy and CMDs and COPD Diabetes CVD and RCTs OR systematic reviews] (917)
100 (exp Child/ or Adolescent/ or exp Infant/) not exp Adult/ (1821899)
101 99 not 100 (869)
Open Grey (www.opengrey.eu/)
25/09/2019
(behavio* NEAR/5 (activation OR activity OR therapy OR "self evaluation" OR "self monitor*" OR modification OR modify* OR contracting
OR reinforc* OR psycho-education OR psychoeducation)) AND depression AND (trial OR trial OR trials OR placebo* OR rct OR random* OR
review* OR overview OR meta-analysis)
23 hits
Open Access Theses and Dissertations (oatd.org)
25/09/2019
Unable to run a simple search for ‘depression’ in this database without it timing out (tried in Google Chrome and Explorer)
ProQuest Dissertations & Theses
25/09/2019
S1 noN("clinical trial*" or "controlled trial*" or random* or "single blind*" or "double blind*" or "research design" or "comparative stud*"
or "evaluation stud*" or "follow-up stud*" or "prospective stud*") 217416
S2 noN(cardio* or cardia* or heart* or coronary* or angina* or ventric* or myocard* or pericard*) OR noN(ischemi* or ischaemi* or
cerebrovasc* or stroke or strokes or apoplexy ) OR noN((brain n/2 accident) ) OR noN(((brain* or cerebral or lacunar) n/2 infarct*)) OR
noN(hypertensi* or hyperlip* or hypercholester* or hypertriglycerid* or cholesterol or "blood pressure") OR noN(emboli* or arrhythmi* or
thrombo* or "atrial fibrillat*" or tachycardi* or endocardi* or "sick sinus") 114420
S3 noN(cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leukemia* or leukaemia*
or metasta*) OR noN(malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*) OR noN(diabet* or asthma or
emphysema* or COPD) OR noN((obstruct* n/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*))) OR noN(((hyper* or
allerg*) n/5 (airway* or respiratory))) OR noN((long-term or longterm or Chronic* or occupational) n/2 (bronchitis or respirat* or lung*) )
OR noN((respiratory n/2 (condition* or disease* or symptom* or problem*))) OR noN("pulmonary hypertension") 156037
S4 S2 OR S3 256439
S5 noN(((behavio* n/1 activat*) or BATD)) OR noN(behavio* and self and (evaluat* or monitor*)) OR noN(reinforc*) OR noN((activit* n/2
schedul*)) OR noN(((pleas* or enjoy* or reward*) n/4 (activit* or event*))) OR noN(((operant or instrumental) n/1 (conditioning or learning)))
OR noN(("positive interaction" OR "positive interactions") or "avoida* coping" or "functional analysis") OR noN(((gain* or reapprais*)
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n/2 focus)) OR noN((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*)) OR noN("environmental contingenc*" or
"contingency management") 86000
S6 noN(behavio* n/1 (counsel* or intervention or train* or treatment or therapy or psychotherapy)) 11146
S7 s5 or s6 94997
S8 noN(depressi* or depressed or dysthymi* or distress* or trauma* or mood*) OR noN("mental health" or "common mental disorder*")
141230
S9 S7 AND S8 AND S1 AND S4 205
PsycINFO 1806 to September Week 2 2019
25/09/2019
1 ((behavio* adj1 activat*) or BATD).tw,id. (2286)
2 behavio*.mp. and (self adj (evaluat* or monitor*)).tw,id. (5812)
3 (behavio* adj2 (contracting or modification or modify*)).tw,id. (8179)
4 reinforc*.ti,id. (26727)
5 (reinforce or reinforcer or reinforcement or reinforcements or re-inforcement or re-inforcements).ab. /freq=2 (15839)
6 (reinforc* adj3 (behavio* or environment* or experience*)).tw,id. (6747)
7 (reinforc* adj1 (positive or contingent)).tw,id. (4594)
8 (activit* adj2 schedul*).tw,id. (587)
9 ((pleas* or enjoy* or reward*) adj4 (activit* or event?)).tw,id. (4210)
10 ((operant or instrumental) adj (conditioning or learning)).tw,id. (5971)
11 (positive interaction* or avoida* coping or environmental contingenc* or contingency management).tw,id. (5673)
12 functional analysis.tw,id. (3141)
13 ((gain? or reapprais*) adj2 focus*).tw,id. (127)
14 ((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*)).ti,ab,id. (4695)
15 behavioral activation system/ (346)
16 or/1-15 [Behavioural Activation] (72175)
17 exp major depression/ (124956)
18 "depression (emotion)"/ (25075)
19 (depressi* or depressed).tw,id. (293646)
20 dysthymi*.tw,id. (3861)
21 distress*.tw,id. (70073)
22 (mood? or mental health or ((emotion* or psychological) adj trauma*)).tw,id. (249686)
23 "common mental disorder*".tw,id. (1760)
24 or/17-23 [Depression - Cochrane terms] (527922)
25 16 and 24 [BA and Depression] (8228)
26 behavior therapy/ (13633)
27 (behavio* adj (counsel* or intervention or train* or treatment or therapy or psychotherapy)).tw,id. (45892)
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28 26 or 27 [Behaviour therapy] (51482)
29 24 and 28 [Behaviour Therapy and Depression] (15673)
30 25 or 29 [BA or Behaviour Therapy AND Depression] (22301)
31 chronic obstructive pulmonary disease/ (1123)
32 bronchial disorders/ or pulmonary emphysema/ (220)
33 asthma/ (4549)
34 lung disorders/ (1658)
35 asthma*.tw,id. (7664)
36 ((long-term or longterm or chronic*) adj5 (bronchitis or respirat*)).tw,id. (675)
37 emphysema*.tw,id. (251)
38 (obstruct* adj3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)).tw,id. (2746)
39 ((hyper responsiveness or hyper-responsiveness or allergy or allergi* or hypersensitiv*) adj5 (airway? or respirat*)).tw,id. (144)
40 ((long-term or longterm or Chronic* or occupational) adj2 lung* adj5 (condition* or disease* or symptom* or problem* or failure*)).tw,id.
(385)
41 (respirat* adj2 (condition* or disease* or symptom* or problem*)).tw,id. (2102)
42 pulmonary hypertension.tw,id. (188)
43 (COPD or COAD or COBD or AECB).tw,id. (1534)
44 or/31-43 [Chronic Respiratory Diseases] (13524)
45 diabetes mellitus/ or exp type 2 diabetes/ (7872)
46 diabet*.tw,id. (30243)
47 (noninsulin*-depend* or non-insulin*-depend* or noninsulin*depend* or non-insulin*depend*).tw,id. (284)
48 (fasting glucose or plasma glucose or glucose tolerance test* or (glyc?emic adj2 control*)).tw,id. (3844)
49 (HbA1c or A1C or A1c or Hb1c or ((glycated or glycosylated) adj h?emoglobin?)).tw,id. (2901)
50 (NIDDM or T2D or T2DM).tw,id. (2051)
51 or/45-50 [Diabetes] (32309)
52 exp cardiovascular disorders/ (59835)
53 (cardio* or cardia* or cvd).tw,id. (49352)
54 (heart* or coronary*).tw,id. (62799)
55 (angina* or ventric*).tw,id. (10534)
56 (myocard* or pericard*).tw,id. (5852)
57 (isch?em* or cerebrovasc*).tw,id. (23405)
58 cerebrovascular accidents/ or exp cerebral ischemia/ (23090)
59 (stroke or strokes or poststroke).tw,id. (33557)
60 apoplexy.tw,id. (146)
61 (brain adj2 accident*).tw,id. (68)
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62 ((brain* or cerebral or lacunar) adj2 infarct*).tw,id. (2733)
63 exp hypertension/ (6968)
64 (hypertensi* or hyperlip*).tw,id. (17842)
65 (hypercholester* or hypertriglycerid*).tw,id. (1093)
66 arteriosclerosis/ (121)
67 cholesterol/ (2100)
68 (cholesterol or arteriosclero* or atherosclero* or peripheral arter* disease*).tw,id. (7869)
69 exp blood pressure disorders/ (7952)
70 blood pressure.tw,id. (19309)
71 (emboli* or arrhythmi*).tw,id. (4531)
72 (thrombo* or "atrial fibrillat*").tw,id. (5145)
73 (tachycardi* or endocardi* or "sick sinus").tw,id. (1694)
74 or/52-73 [CVD] (171715)
75 exp neoplasms/ (49460)
76 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or malignan*
or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog* or psychoongology or psycho-oncology).tw,id. (82444)
77 75 or 76 [Cancer] (83722)
78 44 or 51 or 74 or 77 [COPD Diabetes CVD or Cancer] (273613)
79 exp clinical trials/ or experimental design/ (22409)
80 exp treatment effectiveness evaluation/ (23866)
81 exp mental health program evaluation/ (2075)
82 exp random sampling/ (824)
83 randomi*.tw. (81401)
84 (clinic* adj4 trial*).tw. (35781)
85 (random* adj5 (assign* or allocat* or assort*)).tw. (42856)
86 (crossover or cross-over).tw. (9898)
87 ((singl* or doubl* or tripl* or trebl*) adj (blind* or mask*)).tw. (25366)
88 exp placebo/ (5351)
89 placebo*.tw. (39516)
90 or/79-89 [Trials] (188622)
91 30 and 78 and 90 [BA or Behaviour therapy and CMDs and COPD Diabetes CVD and RCTs] (468)
92 30 and 78 (1558)
93 limit 92 to ("0830 systematic review" or 1200 meta analysis or 1300 metasynthesis) (58)
94 ((systematic adj2 review*) or scoping review* or synthesis or meta-analys* or "meta analysis").ti. (37108)
95 92 and 94 (44)
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96 ("Search filter*" or "search strateg*" or "literature search*").ab. (9274)
97 92 and 96 (13)
98 91 or 93 or 95 or 97 [BA or Behaviour Therapy and CMDs and COPD Diabetes CVD and RCTs OR systematic reviews] (498)
99 ((child* or adolescen*) not adult*).ag. (492563)
100 98 not 99 (483)
World Health Organization trials portal (ICTRP)
25/09/2019
Title: diabet* OR cancer* or neoplas* OR tumor* OR tumour* OR asthma* OR stroke or hypertensi* OR CVD or cardio* OR cardia* OR heart*









H I S T O R Y
Protocol first published: Issue 10, 2019
Review first published: Issue 8, 2020
C O N T R I B U T I O N S   O F   A U T H O R S
EU and NS conceived the idea for this review.
MP led the adaption of the review protocol (Uphoff 2019) from the protocol of the review 'Behavioural activation therapies for depression
in adults' (Uphoff 2020).
EU, MP, DB, DC, PM, MP, and RR participated in screening, data extraction of studies, and risk of bias assessments.
JW designed and performed the searches and revised the 'search strategy' sections of the review.
EU performed the analyses and GRADE assessments.
All authors contributed to the writing of the manuscript.





RC: leads and has responsibility for Cochrane Common Mental Disorders, which has supported parts of the review process and is largely
funded by a grant from the National Institute of Health and Research (NIHR) in the UK.
DC: none.
Behavioural activation therapy for depression in adults with non-communicable diseases (Review)









Cochrane Database of Systematic Reviews
DE: in his role of Chief Investigator, is responsible for the conduct of the ongoing CHEMIST and MODS trials in which behavioural activation
therapies are evaluated. He is the author of several publications reporting on trials of behavioural activation.
EF: co-investigator of "Developing and evaluating an adapted behavioural activation intervention for people with depression and diabetes





NS: co-investigator of "Developing and evaluating an adapted behavioural activation intervention for people with depression and diabetes
in South Asia". Funded by the NIHR in the UK; ref. NIHR200806.
S O U R C E S   O F   S U P P O R T
Internal sources
• Bradford District Care NHS Foundation Trust, UK
• Tees, Esk and Wear Valleys NHS Foundation Trust (TEWV), UK
• University of York, UK
• University of Exeter, UK
External sources
• National Institute for Health Research (NIHR), UK
Cochrane Infrastructure funding to the Common Mental Disorders Cochrane Review Group
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the protocol (Uphoff 2019), we stated that GRADE assessments would be performed by two review authors independently. As this is not
a requirement of Cochrane Reviews, we decided instead that one experienced review author would perform the assessments (EU) and
other review authors would check. Any disagreements were discussed between the review authors.
We had planned to conduct meta-analyses for our prespecified outcomes, but this was not possible for all, but the treatment efficacy
outcome given the small amount of data available from the two included studies. Results were synthesised narratively instead. No
subgroup analyses or sensitivity analyses were performed, except for sensitivity analyses exploring the influence of missing data on the
results.
One study reported multiple outcome domains of the SF-36 relevant to social adjustment and functioning. Given the importance of the
interaction between depression and physical health for the population of this review, we reported the SF-36 physical component.
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